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A B S T R A C T
Background
Alpha-glucosidase inhibitors (AGIs) reduce blood glucose levels and may thus prevent type 2 diabetes and cardiovascular disease in
patients with impaired glucose tolerance (IGT). These possible effects, and the effects on quality of life, plasma lipids and body weight,
have never been investigated in a systematic literature review and meta-analysis.
Objectives
To assess the effects of alpha-glucosidase inhibitors in patients IGT or impaired fasting blood glucose (IFBG), or both.
Search methods
We searched The Cochrane Library, PUBMED, EMBASE, Web of Science, LILACS, databases of ongoing trials, reference lists of
relevant reviews, and we contacted experts and manufacturers.
Selection criteria
Randomised controlled trials of at least one-year duration in patients with IGT or IFBG, or both, comparing AGI monotherapy with
any other intervention.
Data collection and analysis
Two reviewers read all abstracts, assessed quality and extracted data independently. Discrepancies were resolved by consensus or by the
judgement of a third reviewer.
Main results
We included five trials (2360 participants), all investigating acarbose, that included patients with IGT or patients ’at increased risk for
diabetes’ (n = 1). Study duration was one, three (n = 2), five and six years. One study was at low risk of bias and four studies at high
risk of bias. Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were
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not possible. Data from the study at low risk of bias suggests that acarbose decreases the occurrence of type 2 diabetes (NNT = 10),
cardiovascular events (NNT = 50, based on 47 events, study not initially powered for this outcome), post-load blood glucose (-0.6
mmol/L, 95% CI -1.0 to -0.3) and body mass index (0.3 kg/m2, 95% CI -0.1 to -0.5). No statistically significant effects were observed
on mortality, other morbidity, glycated haemoglobin, fasting blood glucose, lipids and blood pressure. The effects on the incidence of
type 2 diabetes were confirmed in two studies at high risk of bias (OR 0.2, 95% CI 0.1 to 0.6). Adverse effects were mostly of gastro-
intestinal origin (OR 3.5, 95% CI 2.7 to 4.4).
Authors’ conclusions
There is evidence that acarbose reduces the incidence of type 2 diabetes in patients with IGT. However, it is unclear whether this should
be seen as prevention, delay or masking of diabetes. Acarbose may prevent the occurrence of cardiovascular events, but this finding
needs to be confirmed in more studies.
P L A I N L A N G U A G E S U M M A R Y
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) are drugs that delay the breakdown of carbohydrates in the gut, and
consequently slow down the absorption of sugars. Patients with type 2 diabetes may use it therapeutically. People with a raised blood
glucose level (without being a diabetes patient) may use this drug in order to prevent developing type 2 diabetes and diabetes related
morbidity such as cardiovascular diseases. To find evidence for these assumptions, we searched the medical literature for randomised
controlled trials of at least one-year duration, investigating alpha-glucosidase inhibitors for patients with impaired glucose tolerance
(IGT) or impaired fasting blood glucose (IFBG). Patients with IGT or IFBG have raised blood glucose levels, but do not meet the
criteria for having type 1 or type 2 diabetes.
In our review we included five studies, representing 2360 participants, investigating acarbose. Of these studies, one was of high quality,
and two did not show exact data, as the results were not available in full publication. The study of high quality yielded that if 10 people
with IGT would take acarbose for three years, one case of diabetes would not occur. This finding was confirmed in studies of lower
quality. The relevance of this finding is questionable because we found only small effects on blood glucose levels, and the mechanism
behind this finding remains unclear: does acarbose really prevent diabetes does it delay the occurrence or mask type 2 diabetes? With
respect to the effect on the occurrence of cardiovascular diseases, a dubious preventive effect of acarbose on the occurrence of myocardial
infarctions was found. However, definitive conclusion could not be drawn and this latter finding should be confirmed in other studies.
We found no statistically significant effects on the occurrence of death, other complications related to IGT, or quality of life. Side effects
were mostly of gastro-intestinal origin (flatulence, diarrhoea).
The low number of studies, the poor quality of four of the included studies, and the missing data of two included studies limited this
review. First, the missing data of two included studies need to be made available for a future update of this review. Next, the results of
the two ongoing studies should be implemented in the review. If, after that, the evidence remains inconclusive, new trials should be
initiated in order to investigate the true value of alpha-glucosidase inhibitors for patients with impaired glucose tolerance or impaired
fasting blood glucose.
B A C K G R O U N D
Description of the condition
Impaired glucose tolerance (IGT) and impaired fasting blood glu-
cose (IFBG) are generally recognised as an expression of abnormal
glucose homeostasis that is not severe enough to meet the crite-
ria for type 2 diabetes mellitus. The term IGT was introduced in
1979. In the past IGT has been called a ’pre-state’ of diabetes or
’prediabetes’ (NDDG 1979). The term IFBG (sometimes referred
to as impaired fasting glycaemia) has been introduced much later
(ADA 1997). IGT and IFBG represent different pathophysiolog-
ical mechanisms: IGT is seen as a characteristic of peripheral in-
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sulin resistance and IFBG is seen as an expression of raised hep-
atic glucose output and a defect in early insulin secretion. On the
other hand, there are many similarities, as both IGT and IFBG are
associated with an increased risk of diabetes and the development
of (diabetes related) complications such as cardiovascular disease
(Unwin 2002). Currently, the criteria for IGT and IFBG are as
follows (plasma venous glucose concentrations):
• IGT - fasting blood glucose less than 7.0 mmol/L and two-
hour post-load blood glucose 7.8 to 11.0 mmol/L;
• IFBG - fasting blood glucose 6.1 to 6.9 mmol/L (two-hour
post-load blood glucose less than 7.8 mmol/L, if measured)
(ADA 1999; WHO 1999). In 2003, the ADA recommended to
change these criteria to 5.6 to 6.9 mmol/L (ADA 2003)
IGT and IFBG cause no symptoms and the condition should be
seen as a risk factor more than a disease itself. It is closely re-
lated to other risk factors of type 2 diabetes such as obesity and
overweight, unfavourable dietary habits and a shortage of exer-
cise. People with IGT or IFBG are at increased risk of developing
type 2 diabetes and cardiovascular disease (even before the onset
of diabetes). Thus, the question arises whether an intervention
in patients with IGT or IFBG could prevent the development of
type 2 diabetes and cardiovascular complications. Life-style inter-
ventions consisting of exercise or diet, or both, showed that the
incidence of diabetes might be reduced (relative risk reduction)
in up to 58% of cases (Pan 1997; Tuomilehto 2001; Knowler
2002). In addition, pharmacological interventions have been in-
vestigated in patients with IGT. Especially drugs that claim to in-
tervene with insulin resistance seem appropriate: biguanides (met-
formin: decreases hepatic glucose output and increases insulin ac-
tion) (Knowler 2002), thiazolidinediones (rosiglitazone, pioglita-
zone: increase insulin sensitivity by increasing glucose utilization
in muscle and liver) (Buchanan 2002) and alpha-glucosidase in-
hibitors (see further).
Description of the intervention
Alpha-glucosidase inhibitors (AGIs) are reversible inhibitors of
alpha-glucosidase, an enzyme present in the brush border of the
small intestine. Currently, three AGIs exist: acarbose, miglitol and
voglibose. Emiglitate, a fourth AGI, is currently not available on
the market. AGIs delay absorption of complex carbohydrates and
thus inhibit postprandial glucose peaks and consequently lower
postprandial insulin levels. In the treatment of type 2 diabetes,
AGIs have been proven to have beneficial effects on glycaemic
control and post-load insulin levels but there is no evidence for a
reduction of mortality or morbidity (Van de Laar 2005).
Potential side-effects are of special importance in the use of med-
ication in persons with IGT or IFBG for two reasons. First, IGT
and IFBG are asymptomatic, so people will, in contrast to poten-
tial side-effects, not notice any direct benefits from the medica-
tion. Second, because of the chronic and long-lasting character of
IGT and IFBG, medication will have to be used for a long period
of time. Therefore, long-term safety is very important. AGIs cause
unfavourable dose-dependent side-effects, mostly flatulence and
other gastro-intestinal side-effects, when compared to placebo or
sulphonylurea. But there is no evidence for long-term detrimental
effects of AGIs (Van de Laar 2005).
Why it is important to do this review
More recently, AGIs have been put into a new light as a result of a
study on the efficacy of acarbose in patients with IGT (Chiasson
2002; Chiasson 2003). This study showed that acarbose could
prevent or delay the development of IGT into type 2 diabetes.
Moreover, it showed a reduced risk of cardiovascular disease and
hypertension in the acarbose treated group. However, the con-
clusions of this study are heavily debated (Chiasson 2004; Kaiser
2004; Sawicki 2004). We have found no systematic review that
focuses exclusively on the efficacy of AGIs for patients with IGT
or IFBG.
O B J E C T I V E S
To assess the effects of alpha-glucosidase inhibitors for people with
impaired glucose tolerance or impaired fasting blood glucose.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials with a minimum du-
ration of one year. Because the common adverse effects of AGIs
make true blinding difficult, both blinded and non-blinded stud-
ies were included. Studies published in any language and all iden-
tified trials, published or unpublished, were investigated.
Types of participants
Patients referred to as having a prediabetic state, that is IGT or
IFBG, or both, existing or newly diagnosed. Changes in diagnostic
criteria, both for IGT or IFBG, or both, or diabetes mellitus type
2 (ADA 1997; ADA 1999; NDDG 1979; Unwin 2002; WHO
1980; WHO 1985; WHO 1999) may have produced variability
in the clinical characteristics of the patients included as well as in
the results obtained. We planned to explore these differences in a
sensitivity analysis.
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Types of interventions
Monotherapy with AGIs (acarbose, miglitol or voglibose) com-
pared with:
• placebo;
• a non-pharmacological intervention (for example: diet
therapy, exercise);
• biguanides (for example, metformin);
• thiazolidinediones (for example, pioglitazone);
• sulphonylurea (for example, glibenclamide);
• meglitinide (for example, nateglinide);
• any other pharmacological intervention.
Types of outcome measures
Primary outcomes
• incidence of type 2 diabetes mellitus: diagnosed with
criteria prevailing at the time of the diagnosis (ADA 1997; ADA
1999; NDDG 1979; WHO 1980; WHO 1985; WHO 1998);
• morbidity related to impaired glucose metabolism, the
metabolic syndrome or type 2 diabetes: vascular complications
(angina pectoris, myocardial infarction, stroke, peripheral
vascular disease, amputation), neuropathy, retinopathy,
nephropathy, erectile dysfunction, and hyperosmolar nonketotic
dysregulation;
• mortality: total mortality, mortality related to impaired
glucose metabolism, the metabolic syndrome or type 2 diabetes
(death from myocardial infarction, stroke, renal disease, or
sudden death, death from hyperosmolar nonketotic coma);
Secondary outcomes
• glycaemic control: glycated haemoglobin levels, fasting and
post-load blood glucose levels;
• plasma lipids (triglycerides, total-, high-density lipoprotein
(HDL)- and low-density lipoprotein (LDL)-cholesterol);
• blood pressure: diastolic and systolic blood pressure;
• fasting and post-load insulin and C-peptide levels;
• body weight (or body mass index);
• adverse effects (for example diarrhoea, stomachache,
flatulence);
• quality of life, assessed with a validated instrument;
• costs.
Specific patient covariates, effect modifiers, confounders
• Compliance.
Timing of outcome assessment (length of intervention)
We assessed a possible influence of treatment duration in a sensi-
tivity analysis.
Search methods for identification of studies
Electronic searches
We used the following sources for the identification of trials:
• The Cochrane Library (2006, Issue 1);
• PUBMED (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi) (contains MEDLINE and a number of additional life
science journals, 1966 to February 2006);
• EMBASE (1974 to October 2005);
• LILACS (www.bireme.br/bvs/I/ibd.htm) from 1986 to
March 2006;
• Web of Science (contains: Science Citation Index Expanded
1945 to February 2006; Social Sciences Citation Index 1956 to
February 2006; Arts & Humanities Citation Index 1975 to
February 2006).
We also searched databases of ongoing trials (latest access
March 2006):Current Controlled Trials (http://www.controlled-
trials.com -with links to other databases of ongoing trials);UKNa-
tional Research Register (http://www.update-software.com/Na-
tional/nrr-frame.html); USA -CenterWatchClinical Trials Listing
Service (http://www.CenterWatch.com/); USA - National Insti-
tutes of Health (http://clinicalstudies.info.nih.gov/); Dutch Trial
Register (Nederlands Trial Register) (http://www.trialregister.nl/).
The described search strategy (see Appendix 1) was used for
PUBMED. For use with EMBASE and Web of Science the strat-
egy was slightly adapted because these databases have different in-
terfaces. The necessary changes in the search string were done in
such a way that the search became more sensitive (that is yields a
higher number of ’hits’). In The Cochrane Library, LILACS and
the databases of ongoing trials we searched with the various text
words for the AGIs and their brand names.
We combined three different search strategies (specified in
Appendix 1):
• for alpha-glucosidase inhibitors we used a strategy used for
a recent systematic review on AGIs (Van de Laar 2005);
• controlled trials we used a sensitive validated search strategy
(Robinson 2002);
• for IGT and IFBG we developed a search strategy
combining keywords (MeSH headings) and text words. We
extensively tested it by running the search and subsequently
investigated whether known key-studies were not included, we
then adjusted the model until we didn’t find any relevant study
that was not found by the search string.
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Searching other resources
Authors of relevant identified studies and other experts were con-
tacted by mail in order to obtain additional references, unpub-
lished trials, and ongoing trials or to obtain missing data not re-
ported in the original trials. Similarly, manufacturers and patent
holders (Bayer AG, Sanofi-Synthelabo, Pfizer, Takeda) were con-
tacted in order to retrieve information on AGIs trials, published
and unpublished.
We searched reference lists of relevant trials and AGI reviews and
selected possible references that were already in our own files.
Data collection and analysis
Selection of studies
Two reviewers (FVDL and PL) independently checked the titles,
abstract sections and keywords of every record retrieved. Full ar-
ticles were retrieved for further assessment when the information
given suggested that the study:
• included patients with IGT or IFBG;
• compared AGIs with placebo or any other control;
• assessed one or more relevant predefined clinical outcomes;
• used random allocation to the comparison groups.
In case of any doubt regarding these criteria from the information
given by the title and abstract, the full article was retrieved for
clarification. Interrater agreement for study selection was assessed
using the kappa statistic (Cohen 1960). A third party (EVDL) re-
solved differences in opinions between the two reviewers. If resolv-
ing disagreement was not possible, the article was added to those
’awaiting assessment’ and the authors were contacted for clarifica-
tion. If no clarification was provided, we planned to consult the
review group editorial base.
Data extraction and management
Two reviewers extracted data on intervention and outcomes inde-
pendently, using a pre-tested data extraction form that was adapted
from a standard form provided by the review group. The data ex-
traction form included the following items:
• General information: author, type of publication
(including the existence of duplicate or multiple publications),
year of publication, language, country where the study was
conducted, setting (general practice, hospital or outpatient/rural,
city, developed/developing world/single or multi-centre), the
stated aim of the study published, sponsor(s), ethics approval;
• Study characteristics: parallel or cross-over, type of control
groups (placebo, other medication etc.), existence of run-in or
wash-out period, or both, description of possible carry-over
effect (for cross-over studies), method, type and quality of
randomisation, method and quality of allocation concealment,
method and quality of blinding, information about handling of
drop-outs, withdrawals and losses to follow-up, numbers of and
reasons for drop-out, method and quality of blinding of outcome
assessment (if applicable), method and quality of blinding of
analyses, existence of possible sub-groups, method of assessment
of compliance;
• Participants: description of diagnostic criteria for IGT or
IFBG, or both, and diabetes mellitus type 2, inclusion and
exclusion criteria;
• Interventions: specification of possible life-style co-
intervention, the nature, dose and regimen of AGI(s) and control
interventions, duration of intervention and follow-up;
• Baseline characteristics and measurements: numbers of
patients, sex, age, ethnicity, socio-economic status and duration
of diabetes, other risk factors for type 2 diabetes or
macrovascular disease (familiar disposition, history of gestational
diabetes, exercise, smoking) existence of significant differences at
baseline, baseline glycated haemoglobin, fasting and post-load
blood glucose, plasma lipids (triglycerides, total-, HDL- and
LDL-cholesterol), height, weight and body mass index (BMI),
fasting and post-load insulin and C-peptide (standard deviations
if applicable), specifications (including reference ranges) of all
laboratory measurements, type of post-load test, time between
fasting and post-load measurements, centralisation of laboratory
measurements, assessment of health-status, definitions of health
outcomes (for example myocardial infarction, heart failure, renal
failure);
• Outcomes: total and disease specific deaths and morbidity,
quality of life (including method of assessment), mean changes
(standard deviation, SD) of the following values: glycated
haemoglobin, fasting and post-load blood glucose, lipids, fasting
and post-load insulin / C-peptide, body weight, BMI, occurrence
of adverse events (total and gastro-intestinal), compliance, costs.
Differences in data extraction were resolved by consensus, refer-
ring back to the original article. If necessary, information was
sought from the authors of the original studies. If necessary, we
also planned to extract data from graphical figures: two reviewers
(FVDL and PL) would calculate the data independently and if
both outcomes were not similar, a third reviewer (EVDL) would
recalculate the data. A statistician checked all extracted data for
errors, after transfer to the database.
Assessment of risk of bias in included studies
The two reviewers (FVDL and PL) assessed each trial indepen-
dently. Possible disagreement was resolved with consensus, or with
consultation of a third reviewer (EVDL) in case of disagreement.
We assessed the following quality items:
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Minimisation of selection bias
• randomisation procedure: the randomisation procedure was
scored ’adequate’ if the resulting sequences were unpredictable
(for example computer generated schemes, tables of random
numbers, coin tossing).
• allocation concealment: allocation concealment was scored
’adequate’ if participating patients and investigators could not
foresee the assignment (for example by central randomisation
remote from trial site, sequentially numbered and sealed radio-
opaque envelopes).
Minimisation of performance bias
• method of blinding: blinding was scored ’adequate’ if the
two (or more) drugs / pills were similar in size, colour and shape
or when a double-dummy method was applied. Because of the
sometimes-obvious adverse effects of AGIs, true blinding is
difficult. For trials that reported blinding of patients for
medications, we also investigate whether blinding was checked
(for example by asking patient and investigator afterwards about
the medication they suspected to have been supplied with).
Minimisation of attrition bias
• handling of drop-outs: handling of drop-outs was
considered ’adequate’ when studies reported a complete
description of all patients failing to participate until the end of
the trial and if the data were analysed on intention-to-treat
(ITT) basis, that means with all randomised patients included.
• quantity of dropouts: overall dropout rate less than 15%
was considered ’adequate’.
• selective dropout: a difference in dropout rates between the
main treatment groups less than 10% was considered ’adequate’.
Minimisation of detection bias
• method of blinding outcome-assessment: outcome
assessment was considered ’adequate’ if the outcome assessors
were completely blind for the intervention. This item was
considered less relevant for studies with laboratory data or death
as main outcomes.
• method of blinding of analysis: this was considered
’adequate’ if the outcome assessors (investigators, statisticians)
were completely blind for the intervention up to the point that
all analyses were completed. Blinding of analyses is to date not a
common practice in the conduct of randomised trials. Therefore
we only planned to explore possible influences of blinded
analyses in a sensitivity analysis and we did not plan to use this
item for the overall quality assessment.
Following these criteria, studies were broadly subdivided into the
following three categories using an adapted version of theCochrane
Handbook for Systematic Reviews of Interventions criteria:
A - All quality criteria met (1. adequate randomisation and alloca-
tion concealment, 2. adequate blinding, 3. adequate ITT analysis
or both drop-out rate less than 15% or selective drop-out less than
10%, or both 4. adequate blinding outcome-assessment): low risk
of bias.
B - One or more quality criteria only partially met (1. inadequate
randomisation or inadequate allocation concealment, 2. mention-
ing of blinding but exact method unclear, 3. inadequate/unclear
ITT analysis but drop-out less than 15% or selective drop-out less
than 10%, 4. mention of blinding outcome-assessment but exact
method unclear): moderate risk of bias.
C - One or more quality criteria not met (1. inadequate randomi-
sation and allocation concealment, 2. inadequate or no blinding,
3. inadequate ITT and drop-out rate equal to or greater than 15%
and selective drop-out equal to or greater than 10%, 4. inadequate
blinding outcome-assessment): high risk of bias.
We explored the influence of individual quality criteria in a sensi-
tivity analysis (see under ’sensitivity analyses’). The two reviewers
discussed all quality items. In cases of disagreement, a third re-
viewer was planned to be consulted (EVDL).
Data synthesis
The table of comparison was divided in all possible comparisons
first (for example acarbose versus placebo), then sub-divided into
all possible outcomes (for example death, glycated haemoglobin,
adverse events) and finally, within the outcome sub-groups were
made for the different dosages. Outcomes were calculated per sub-
group and for all sub-groups together.
Dichotomous data were expressed as relative risks (RR). We calcu-
lated the risk difference (RD) and we converted the RD into the
number needed to treat (NNT) or the number needed to harm
(NNH) taking into account the time of follow-up.
Continuous data were expressed as weighted mean differences
(WMD) and an overall WMD was calculated. We used the dif-
ferences from baseline to endpoint as the actual measure of ef-
fect of all continuous variables. The standard deviations of these
differences are essential for the data to be included in the meta-
analysis. If the standard deviation (SD) of the difference were not
reported, we first asked the authors to provide these data. If the
SDs were not provided we estimated the SD of the difference with
the following formula:
SDpaireddiff erence =
√
[(SD1)
2 + (SD2)
2 - 2 x r x SD1 x SD2].
SDpaireddiff erence = standard deviation of the difference (pre- /
post-treatment)
SD1 = Standard deviation of the pre-treatment value, SD2 = Stan-
dard deviation of the post-treatment value, r = correlation coeffi-
cient. We used a conservative correlation coefficient of 0.4.
Overall results were calculated based on the random effects model.
Heterogeneity was statistically tested by using the Z score and the
χ2- statistic with significance set at P < 0.10. Quantification of
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the effect of heterogeneity was assessed by means of I2, ranging
from 0% to 100% including its 95% confidence interval (Higgins
2002). I2 demonstrates the percentage of total variation across
studies due to heterogeneity and was used to judge the consistency
of evidence. Possible sources of heterogeneity were (planned to be)
assessed by subgroup, sensitivity and meta-regression analyses as
described below.
The analyses were done with Review Manager (RevMan 4.2).
Subgroup analysis and investigation of heterogeneity
We planned to investigate main outcome measures by subgroup
analyses in order to explore differences in effect as follows:
• glycated haemoglobin level at baseline (subdivided into
groups, based on data);
• age (subdivided into groups, based on data);
• gender (subdivided into groups, based on data);
• body mass index (BMI) (subdivided into groups, based on
data);
• different kinds of life-style co-interventions used (that is
dietary advice, exercise, help with smoking cessation, combined
interventions);
• duration of intervention (subdivided into groups, based on
data);
• use of an individually titrated versus fixed dose of AGI;
• use of a step-up dose versus administering the full dose
immediately.
Sensitivity analysis
We planned to perform sensitivity analyses for a number of factors
by comparing the results of the meta-analysis for studies with
and without certain characteristics. Data from a minimum of five
studies had to be available for both groups to be considered.
The following factors were planned to be investigated:
• comparing published and unpublished studies;
• comparing studies with and without (or with unknown)
quality characteristics: adequate randomisation, adequate
allocation concealment, adequate method of blinding, adequate
ITT analyses, adequate blinding of outcome-assessment (if
applicable), adequate method of blinding of analyses. Further,
comparing studies with an overall drop-out rate of more than or
equal to 15% and less than 15%, differences in drop-out rates
less than 10% and more than or equal to 10% between the main
treatment groups. In addition, the overall score for quality based
on the Cochrane criteria was used (studies with score A and B
compared to studies with C);
• repeating the analyses excluding trials using the following
filters: diagnostic criteria (patients with IGT or IFBG, or both),
language of publication, source of funding (industry versus other
or no sponsoring) or country;
• repeating the analyses using different measures of effect size
(relative risk, risk difference) and different statistical models
(fixed and random effects models);
• repeating the analyses excluding large studies or studies
with a long duration (based on data) to establish how much they
dominate the results;
• repeating the analyses excluding studies in which other risk
factors for the development of type 2 diabetes or macrovascular
disease were not equally distributed between treatment groups.
Meta-regression analyses
Weplanned to use meta-regression analyses (in SAS procMIXED,
version 8.0) to explore the influence of characteristics of study
population and study design on the outcomes. We planned to
examine all dependent variables for which sufficient studies are
available; the minimal number of studies would need to be 10
to gain sufficient power. The independent variables were similar
to the pre-defined sub-groups. The weight of each trial would be
equal to the inverse sum of the within trial variance and the resid-
ual between trial variance, in order to perform a random effects
analysis.
Assessment of small study bias
Small study bias was planned to be tested by using the funnel plot
or other corrective analytical methods depending on the number
of clinical trials included in the systematic review (Begg 1994;
Egger 1997; Hedges 1992).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Trials identified (see Figure 1)
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Figure 1. Study flow-diagram.
PUBMED: 224 records were retrieved and assessed on basis of
title or abstract, or both (until 22 March 2006), 13 records were
initially included for further reading and 12 were included in the
final review.
EMBASE: 551 records were retrieved and assessed on basis of title
or abstract, or both (until 21 October 2005), 20 records were
initially included for further reading and 19 were included in the
final review.
The Cochrane Library: 432 records were retrieved and assessed on
basis of title or abstract, or both (Issue 1, 2006), 10 records were
initially included for further reading. All of those records remained
included in the final review.
Web of Science: 117 records were retrieved and assessed on basis
of title or abstract, or both (until 7 February 2006); eight records
were initially included for further reading. All of those records
remained included in the final review.
LILACS: 95 records were retrieved and assessed on basis of title or
abstract, or both (until 7 February 2006). None of these references
were initially included.
Experts: We obtained two references by corresponding with ex-
perts or authors. One of those references was deemed interesting
and could be included in the final review (EDIT).
Manufacturers: Bayer is the developer of acarbose andmiglitol and
Takeda the developer of voglibose. Sanofi-Synthelabo is patent
holder of miglitol. Bayer send us four references, four were initially
included and three were finally included in the review. Takeda and
Sanofi did not reply to our letters.
Handsearching (checking references of existing reviews, browsing
on the Internet, posters on congress etc.): Twenty-one references
found by handsearching seemed possibly interesting based on title
or abstract, or both. Nineteen references were finally included.
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Databases for ongoing trials: we retrieved 43 records, four of which
were initially included (last searchMarch 22nd 2006). Thus far, we
did not receive any (un)published data that gave cause to exclude
those studies for the review. Two of those studies were finished
by the time of retrieval (DAISI; EDIT) and two other studies
were started in 2005 and will be completed in 2009 (ABC-Study)
and 2013 (Tamita 2006) (see Characteristics of ongoing studiese
Characteristics of ongoing studies).
Interrater agreement
Interrater kappa for agreement on inclusion, calculated on basis of
the first 1210 titles or abstracts, or both, read by the two reviewers
(FVDL and PL) was 0.77 (95% CI 0.65 to 0.90). All differences
in opinion were resolved by consensus.
Included studies
Five studies with 2360 participants, described in 36 articles, ab-
stracts or web sites were finally included in the review. Details are
given in Characteristics of included studies.
Missing data
We contacted all authors for data clarification and missing data.
This was successful for one study (STOP-NIDDM). The corre-
sponding author of the DAISI study sent us the full statistical re-
port with the restriction that we were not allowed to use the data
before their manuscript was accepted for publication. The authors
of the EDIT study promised us to sent more details once their
manuscript was in the galley-proof stage. For the other two stud-
ies the authors did not reply to our letters and mails (Fang 2004;
Wang 2000).
Publication type
Three studies were (predominantly) published as journal arti-
cles (Fang 2004; STOP-NIDDM; Wang 2000). For the STOP-
NIDDM study we also considered correspondence and debate ar-
ticles as a result of the main publications. The other two stud-
ies were published on a web site or as abstracts, or both (DAISI;
EDIT).
Participants
Three studies included patients with IGT according to theWHO
criteria of 1985 (DAISI; Fang 2004; Wang 2000). One study
included participants with IGT according to theWHO criteria of
1999 in addition to a fasting blood glucose equal or greater than
5.6 mmol/L and less than 7.8 mmol/L (STOP-NIDDM) and one
study included participants at increased risk for type 2 diabetes’
with a fasting BG 5.5 to 7.7 mmol/L (EDIT). In the STOP-
NIDDMstudy patients were (mainly) recruited through screening
of high-risk patients and followed as outpatients in study-centres.
In the EDIT study the patients were ’self-referred’ but the exact
setting was unclear. Setting and recruitment for the other studies
remained unclear, thus far.
Trial design
All studies had a parallel design. One study had a double-blind
2x2 factorial design (EDIT). Two studies were blinded (DAISI;
STOP-NIDDM) and two studies were not blinded (Fang 2004;
Wang 2000).
All studies investigated acarbose as the alpha-glucosidase inhibitor
and compared it to placebo (DAISI; EDIT; STOP-NIDDM),
metformin (EDIT; Fang 2004), diet and exercise (Fang 2004) or
treatment, or both (Fang 2004; Wang 2000). Thus far, we found
no completed studies with miglitol or voglibose.
Study duration was six years (EDIT), five years (Fang 2004), three
years (DAISI; STOP-NIDDM) and one year (Wang 2000). In one
study the treatment durationwas followedby a threemonthswash-
out period (placebo given for both groups, STOP-NIDDM), In
all other cases treatment duration was similar to the follow-up
duration.
Outcome measures
All studies reported occurrence of type 2 diabetes as a primary out-
come. Data on cardiovascular morbidity and mortality was avail-
able for the STOP-NIDDM study only. For two studies addi-
tional data for glycaemic control, lipids, blood pressure and body
weight were available (Fang 2004; STOP-NIDDM). The DAISI
and EDIT study reported, that they investigated a number of ad-
ditional outcomes (for example plasma glucose, lipids) but these
data were not accessible for us thus far.
Excluded studies
Three studies were initially included but excluded after reading
the full article. Two studies turned out to be not randomised (
Mangiagli 2004; Yang 2001) and one study included patients with
type 2 diabetes (EDIP).
Risk of bias in included studies
With respect to selection bias only one study had both an adequate
randomisation and allocation concealment (STOP-NIDDM).
The risk of attrition bias was low in three studies. However, no
study had adequate intention-to-treat analysis. Blinding (perfor-
mance bias) was adequate in one study (STOP-NIDDM) and
for two studies information was lacking about precise methods of
blinding (DAISI; EDIT). In one study outcomes were adequately
assessed in a blinded fashion (STOP-NIDDM) (see Table 1).
The overall quality was roughly assessed on a three-point scale
according to the Cochrane Handbook for Systematic Reviews of In-
terventions: one study scored A (low risk of bias) and four studies
scored C (high risk of bias).
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Effects of interventions
With one exception, we were unable to perform meta-analyses in
this review because for none of the comparisons data were available
from more than one study.
Acarbose versus placebo (see appendix 2 and data
and analyses section)
Three studies compared acarbose with placebo (DAISI; EDIT;
STOP-NIDDM).However, only for one study sufficient datawere
available to allow statistical comparison (STOP-NIDDM). For
the other two studies most of the data are not yet available (DAISI;
EDIT).
Mortality, incidence of type 2 diabetes and cardiovascular
disease
No significant effects on total mortality and mortality due to car-
diovascular causes were found (STOP-NIDDM). Data for the
other two studies were missing (DAISI; EDIT).
Acarbose reduced the incidence of (conversion to) type 2 diabetes
in the acarbose group: RR 0.78 (95% CI 0.68 to 0.90), Risk
difference (RD) 0.09 (95% CI 0.04 to 0.14), Number Needed to
Treat (NNT) = 10 (STOP-NIDDM). TheNNT indicates that 10
patients have to be treated for three years with acarbose in order
to prevent one case of type 2 diabetes. Also, in the EDIT-study
it was reported that the use of acarbose had a preventive effect on
the incidence of type 2 diabetes: RR 0.66 (P = 0.046).
In the STOP-NIDDM study a decreasing effect for acarbose on
the incidence of cardiovascular disease as a combined endpoint
(myocardial infarction, angina, revascularization procedures, car-
diovascular death, congestive heart failure, cerebrovascular events
and peripheral vascular disease) was found: RR 0.47 (95%CI 0.26
to 0.86). Also, a decreasing effect on myocardial infarctions (RR
0.08 (95% CI 0.01 to 0.64) was found. The RDs were 0.02 (95%
CI 0.01 to 0.04; NNT = 50) and 0.02 (95% CI 0.01 to 0.03;
NNT = 50) respectively. No significant differences in the inci-
dence of angina pectoris, revascularization procedures, congestive
heart failure, cerebrovascular events or peripheral vascular events
were found. In total, 47 events took place in the whole study pop-
ulation and the study was not initially powered for this outcome.
Thus far, we found no data on cardiovascular morbidity from the
EDIT and DAISI studies.
Glycaemic control
Acarbose decreased post-load glucose by 0.61 mmol/L (95% CI
0.27 to 0.95). No significant effects on glycated haemoglobin and
fasting blood glucose were observed (STOP-NIDDM).
In the EDIT study acarbose decreased fasting blood glucose by 0.1
mmol/L (P = 0.0043) and post-load blood glucose by 0.4 mmol/
L (P = 0.0075).
Plasma lipids
No significant effects on lipids were found (STOP-NIDDM) or
no data were available (DAISI; EDIT).
Blood pressure
In our analysis, we found no significant effects on diastolic and
systolic blood pressure (Comparison 1, outcomes 41 & 42). How-
ever, in one study the authors reported a beneficial effect on the in-
cidence of newcases of hypertension (whichwas not an outcome in
our review) (STOP-NIDDM). In the acarbose and placebo groups
78 and 115 patients developed hypertension respectively (hazard
ratio 0.66, 95% CI 0.49 to 0.89). Hypertension was defined as a
blood pressure greater than 140/90 mmHg on two visits or if the
family physician added antihypertensive medication. It is remark-
able that at baseline almost half of all patients were already diag-
nosed with hypertension (acarbose 357/682, placebo 345/686),
but these participants were kept in the analysis for the develop-
ment of hypertension. No data on blood pressure was available for
the other studies with the comparison acarbose-placebo (DAISI;
EDIT).
Fasting and post-load insulin and C-peptide
No significant effects on fasting and post-load insulin levels
were found (STOP-NIDDM) or no data were available (DAISI;
EDIT).
Body weight
Acarbose decreased body weight by 1.2 kg (95% CI 0.5 to 1.8)
and BMI by 0.3 kg/m2 (95% CI 0.1 to 0.5). For the other studies
(DAISI; EDIT), no data were available.
Adverse events
Acarbose caused more gastro-intestinal side effects compared to
placebo: RR 1.40 (95% CI 1.31 to 1.50) and RD 0.24 (95% CI
0.20 to 0.29; Number Needed to Harm (NNH) = 4). For the
other studies, no data were available.
Quality of life
We found no data for ’quality of life’, although it was stated for
the EDIT study that this outcome would be measured.
Costs and compliance
Resource consumption data were not systematically collected in
the STOP-NIDDM study. A cost-effectiveness study was pub-
lished in which the likely consumption of healthcare resources
were estimated and used for analyses.
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It was reported that compliance was assessed by pill counting but
we found no outcome data in the published articles. We failed to
ask for those data in our correspondence with the authors.
Adjustment for high discontinuation rate in the
acarbose arm of the STOP-NIDDM study (see
appendix 3)
One of the main criticisms on the STOP-NIDDM study was that
the discontinuation rate in the acarbose group was higher than in
the placebo group (acarbose 31% versus placebo 19%). Despite
the fact that discontinuing patients remained in the ITT analyses,
it was suggested that those patients were not followed-up regularly
every three months and thus possible occurrence of diabetes or
a cardiovascular event was less likely to be discovered (Sawicki
2004).
In order to investigate the possible influence of differences in the
frequency of follow-up, we re-analysed the data with the following
adjustments: first we requested for themean number of study visits
for both treatment groups. Next, we divided the number of visits
of the placebo group by the number of visits in the acarbose group.
We used this outcome as correction factor for the number of events
in the acarbose group (occurrence of cardiovascular morbidity and
type 2 diabetes).
The authors of the STOP-NIDDM study reported that the mean
numbers of study visit in the acarbose (n = 682) and in the placebo
group (n = 686) were 13.3 (SD = 5.4) and 14.6 (SD = 4.3) re-
spectively. The calculated correction factor was: 14.6/13.3 = 1.1.
The outcomes before and after this correction factor are listed in
Appendix 3. The effects sizes (Odds Ratios) of the outcomes for
incidence of type 2 diabetes and occurrence of any cardiovascu-
lar disease became smaller after the correction but remained sta-
tistically significant. The (statistically significant) effects size for
myocardial infarctions did not change (due to the fact that there
was only one case in the acarbose group). The other outcomes
remained statistically not significant after correction.
Acarbose versus metformin (see appendix 4 and data
and analyses section)
One study investigated both agents in a 2x2 factorial design (
EDIT). From this study no data on the comparison acarbose versus
metformin is available thus far.
Another study directly compared acarbose with metformin (Fang
2004). Acarbose showed a decreasing effect on post-load blood
glucose compared to metformin: 1.40 mmol/L (95% CI 0.55 to
2.25). Metformin showed a statistically significant decreasing ef-
fect on total cholesterol (0.90 mmol/L, 95% CI 0.19 to 1.61) and
diastolic blood pressure (6 mmHg, 95% CI 2.81 to 9.19) com-
pared to acarbose. No significant effects for acarbose ormetformin
were found for the effect on incidence of type 2 diabetes, fasting
blood glucose, triglycerides, BMI or systolic blood pressure. Data
for cardiovascular events, quality of life, insulin or C-peptide lev-
els, costs, compliance or adverse events were not found.
Acarbose versus diet and exercise (see appendix 5
and data and analyses section)
One study investigated the comparison acarbose versus diet and
exercise (Fang 2004). In this study a beneficial effect of acarbose
compared to diet and exercise was found on the incidence of type
2 diabetes: RR 0.40 (95% CI 0.17 to 0.96), Risk difference (RD)
0.20 (95% CI 0.02 to 0.38, NNT = 5).
Further, acarbose significantly reduced fasting blood glucose (-
1.37mmol/L, 95%CI -0.50 to -2.24) and post-load blood glucose
(-2.79 mmol/L, 95% CI -1.79 to -3.79). Effects on total choles-
terol, triglycerides, body weight and BMI were not statistically
significant. Data for cardiovascular events, quality of life, insulin
or C-peptide levels, costs, adverse events or compliance were not
found.
Acarbose versus no treatment (see appendix 6 and
data and analyses section)
Two studies compared acarbose with no treatment (Fang 2004;
Wang 2000).
Mortality, incidence of type 2 diabetes and cardiovascular
disease
The combined results of the two studies indicated that acarbose
reduced the incidence of type 2 diabetes: RR 0.31 (95%CI 0.14 to
0.69), Risk difference (RD) 0.17 (95% CI -0.09 to 0.43, NS).We
found no data for effects on mortality or cardiovascular morbidity.
Glycaemic control
One study reported data for the effects on fasting and post-load
blood glucose.Compared topatientswhowere givenno treatment,
acarbose significantly reduced fasting blood glucose (-1.39 mmol/
L, 95% CI -0.54 to -2.24) and post-load blood glucose (-4.53
mmol/L, 95% CI -3.54 to -5.52) (Fang 2004).
Plasma lipids
One study reported data for the effects on total cholesterol and
triglycerides. Compared to patients who were given no treatment,
acarbose significantly reduced total cholesterol (-1.00 mmol/L,
95% CI -0.194 to -1.81) (Fang 2004).
Blood pressure
One study reported data for the effects of acarbose on diastolic
and systolic blood pressure: no significant effects were found (Fang
2004).
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Fasting and post-load insulin and C-peptide
No data were found for insulin or C-peptide levels.
Body weight
Data were available from one study: compared to patients with no
treatment acarbose showed a non-significant effect on BMI (-1.1
kg/m2, 95% CI -2.2 to 0, P = 0.05) (Fang 2004).
Adverse events
One study reported data on adverse effects (Wang 2000). Two
patients in the acarbose group and no patients who received no
treatment reported adverse effects. The difference was not statis-
tically significant.
Quality of life
We found no data for effects on quality of life.
Costs, compliance
No data were found for these outcomes.
Sensitivity analyses, sub-group analyses, meta-
regression analyses, small study bias
Due to the low number of included studies no further analyses
could be performed.
Heterogeneity
Because not more than a maximum of two studies could be in-
cluded per (statistical) comparison, formal testing of heterogeneity
was not performed.
The studies were reasonably homogeneous with respect to a num-
ber of important items:
• all trials used acarbose as the alpha-glucosidase inhibitor (all
with a dosage of 50 mg TID, except for the STOP-NIDDM
study in which a dosage of 100 mg TID was given);
• all trials focused on patients with IGT (instead IFBG),
except for the EDIT study which included patients ’at risk’ for
developing diabetes (with a fasting blood glucose 5.5 to 7.7
mmol/L);
• in all trials the number of included females and males were
almost similar, ranging from 47% females (Fang 2004) to 51%
females (STOP-NIDDM);
• all trials included patients with a similar age, ranging from a
mean of 49.1 years (Fang 2004) to 63.5 years (Wang 2000).
The following items could cause possible heterogeneity:
• two studies were performed in an Asian population (Fang
2004; Wang 2000). The effects of alpha-glucosidase inhibitors
may be different from European or American populations (the
other trials) due to differences in amount and type of
carbohydrate in the regular diet;
• the mean BMI ranged from a normal BMI (Wang 2000) to
overweight (Fang 2004; EDIT) or obesity (STOP-NIDDM). It
was unknown for the DAISI study;
• baseline glycated haemoglobin was below 6.0% in two
studies (EDIT; STOP-NIDDM), but unknown for the other
studies;
• in two trials, all participants received additional advice on
diet and life-style (STOP-NIDDM; Wang 2000) but for the
other trials this information was missing.
D I S C U S S I O N
Summary of main results
In this systematic reviewwe found evidence fromone large study of
high quality (STOP-NIDDM) that acarbose compared to placebo
reduces the incidence of type 2 diabetes and myocardial infarc-
tions in patients with impaired glucose tolerance. These findings
could not be confirmed nor refuted by two other (but highly sim-
ilar) studies because most data were not available thus far (DAISI;
EDIT). Two smaller studies of low quality comparing acarbose
with no treatment or exercise, confirmed the capacity of acarbose
to reduce the incidence of type 2 diabetes. Effects on cardiovas-
cular morbidity could not be confirmed in other comparisons.
Moreover it should be noted that the effects on cardiovascular
morbidity in the STOP-NIDDM study were based on a limited
number of events and the study was not initially powered for this
outcome. Compared to placebo, acarbose induces more gastro-
intestinal side-effects (NNH = 4).
Decrease in incidence of type 2 diabetes mellitus
We found evidence from several studies that acarbose reduces the
incidence of type 2 diabetes (Fang 2004; STOP-NIDDM; Wang
2000). A firm effect on the incidence of type 2 diabetes is not
surprising. After all, acarbose has a clear effect on glycaemic control
in patients with type 2 diabetes (Van de Laar 2005). Such a drug
will have large effects on the ’incidence’ of diabetes for people who
are at the border of fulfilling the criteria for type 2 diabetes. So, the
question is whether acarbose prevents, delays or even masks type 2
diabetes. The authors of the STOP-NIDDM study are undecided,
as they sometimes speak of ’prevention’ (in the title) and sometimes
of ’delay’ (in the summary) (Chiasson 2002). Critics of the STOP-
NIDDMstudy suggested that acarbosemasks type 2 diabetes since
15,4% of the patients on acarbose compared to 10,6% (placebo)
converted to diabetes during a three months wash-out phase (
Kaiser 2004).
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To assess the value of acarbose with respect to the effects on the
development of type 2 diabetes, it is probably more straightfor-
ward to look at the effects on glycaemic control. After all, IGT
refers to an intermediate state between normal glucose homeostasis
and type 2 diabetes. In the STOP-NIDDM study these effects are
disappointing: no significant effect on glycated haemoglobin and
fasting blood glucose, and a small effect on post-load blood glu-
cose (-0.61 mmol/L, 95% CI -0.95 to -0.27) were found. Those
effects are smaller than obtained in a Cochrane review on alpha-
glucosidase inhibitors for patients with type 2 diabetes (Van de
Laar 2005). This may be explained by the fact that in the be-
fore mentioned review it was found that the effects on glycaemic
control were less strong with lower baseline values of glycaemia
and longer study duration. Further, most trials in the Cochrane
review studied post-load glucose with a full meal tolerance test,
and not an oral glucose tolerance test (OGTT) as has been done
in the STOP-NIDDM study. Acarbose has no direct effects on an
OGTT as alpha-glucosidase inhibitors only delay the breakdown
of complex polysaccharides (and not monosaccharide such as glu-
cose). In this light, the decreasing effect of acarbose on a 2 hours
OGTT is positive because it indicates a beneficial effect of insulin
resistance.
Another argument in the question whether an effect of acarbose
on the incidence of type 2 diabetes is relevant or important, is the
desirability of a drug intervention in people at high risk for type
2 diabetes. It is well recognized that the increase in the number
of patients with type 2 diabetes is in life-style factors such as a
shortage of exercise and an unhealthy diet. Focussing on drugs as
the solution of the problem may distract people from the issues
that are truly important: eat less and exercise more.
Finally the question arises whether true (primary) prevention of
type 2 diabetes with a single drug is possible at all. Type 2 diabetes
is a very complex disease in which many pathophysiological mech-
anisms are involved (for example insulin sensitivity, blood pressure
regulation). Only when one predominant mechanism would be
identified, primary prevention by a drug targeting this mechanism
would be feasible. Currently, it seems not likely that this will be the
case for type 2 diabetes in the near future. In the mean while, drug
interventions for IGT or IFBG should be regarded as secondary
or tertiary prevention.
Decrease in incidence of cardiovascular disease
The observed beneficial effects on the occurrence of cardiovascular
morbidity (STOP-NIDDM) are very interesting. However, these
results should be interpreted with great prudence. This is under-
lined by the authors who sensibly stated that because effects on
cardiovascular morbidity were secondary objectives and the num-
ber of events relatively small, they should be seen as hypothesis
generating (Chiasson 2004).
Critics mentioned the skewed discontinuation rate as another ex-
planation for the observed effects, other than an effect of acar-
bose (Sawicki 2004). Because more patients in the acarbose group
stopped taking their medication (mostly due to side-effects), the
patients in the acarbose group were not followed-up as regular as
the patients in the placebo group and could have had therefore
less chance to be ’detected’ in case a cardiovascular event had taken
place.We re-analysed the data accounting for differences in follow-
up rate and found that the odds ratios for the occurrence of any
cardiovascular event became less strong, but remained statistically
significant.
Another explanation could be in the existence of (unknown) con-
founding factors. Clues for differences in treatment groups were
reported in the cost-effectiveness sub-study of the STOP-NIDDM
trial (Quilici 2005). Baseline risk profiles were determined with a
formula for the identification of high risk for type 2 diabetes (Stern
2002) or cardiovascular risk (Anderson 1991). Based on these risk
scores, it was stated that ’... more placebo patients than acarbose-
treated patients were represented in the high-risk subgroups...’.
So, patients in the placebo group could have had a higher a-priori
risk than patients on acarbose.
We conclude that the observed effects of acarbose on cardiovas-
cular disease may be due to a treatment effect or to (unknown)
confounding factors, or both. The results from the ongoing stud-
ies are needed to confirm or refute the observed effects in the
STOP-NIDDM study (ABC-Study; Tamita 2006).
Effects on incidence of hypertension
We could not confirm the beneficial effects on hypertension ob-
served in the STOP-NIDDM study, in which hypertension was
studied as a clinical outcome (blood pressure greater than 140/
90 mmHg on two or more occasions). Instead we studied the dif-
ferences in diastolic and systolic blood pressure. These outcomes
yielded no statistically significant effects of acarbose compared to
placebo (STOP-NIDDM), and a detrimental effect of acarbose
compared to metformin in one study of low quality and a low
number of participants -6 mm Hg (95% CI 3 to 9) (Fang 2004).
Potential biases in the review process
One of the main strengths of this review is the rigourness and
completeness of the search. It is remarkable that only one trial
(STOP-NIDDM) was listed in the database that is mostly used by
clinicians all over the world (PUBMED), and that the other stud-
ies were retrieved from less well-known databases (EMBASE or
The Cochrane Library), in databases of ongoing trials or by hand-
searching. Second, the a priori decision to include randomised tri-
als only with a duration of at least one year ensured a ’minimum
level’ of quality. Third, we assessed many different outcomes in
the review which enables the readers to judge by themselves what
matters most for their own particular question. Finally, we think
that the tables and figures and the extensive provision of all out-
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come data and information related to quality and heterogeneity,
makes the review transparent.
It is clear that the main limitations are the missing data, espe-
cially from the EDIT and DAISI studies. The authors have kindly
promised their help once their manuscripts are accepted for pub-
lication, but it is remarkable that these important studies have not
been accepted for publication to date (May 2006). This points to
a possible time lag bias: a kind of reporting bias in which stud-
ies may be published rapidly or delayed depending on the nature
and direction of the results. Of course we will use upcoming data
from these studies, and from the studies that are still going on in
future updates of our review. Another limitation is the external
validity of the results. Only for one study the recruitment of the
participants was clearly described. It is important to know how
selection took place in order to be able to generalize the results to
other clinical settings. For example, were the participants volun-
teers recruited with an newspaper advertisement (and thus highly
motivated), or were they recruited from the files of general practi-
tioners (andmaybe less motivated). Further, we only found studies
with acarbose as the AGI. The question whether the results may
be extrapolated to miglitol or voglibose depends on the existence
of a possible group effect for AGIs. The answer to this question
is not known, although in the Cochrane review on AGIs for type
2 diabetes comparable results for acarbose and miglitol were ob-
tained for most outcomes (Van de Laar 2005).
Agreements and disagreements with other
studies or reviews
As far as we are aware of, no systematic review has been done
with an exclusive focus on alpha-glucosidase inhibitors for peo-
ple with IGT of IFBG. Nevertheless, alpha-glucosidase inhibitors
have been studied as part of a recent systematic review on all
kind of drug therapy to delay or prevent type 2 diabetes (Padwal
2005). In that review two studies on acarbose were included: the
STOP-NIDDM study, and a non-randomised study (Yang 2001)
(excluded for the current review). It was concluded that acarbose
reduced the incidence of type 2 diabetes compared with placebo
but that it could not definitively be recommended for diabetes
prevention. Similar conclusions were drawn formetformin, trogli-
tazone and orlistat (a weight reducing agent). Further, inconclu-
sive results for a decrease in the incidence of type 2 diabetes were
reported for cholesterol lowering agents (fibrates and statins), an-
tihypertensive agents and oestrogens. A systematic review on the
efficacy of lifestyle education concluded that lifestyle education
was clearly effective for reducing two-hour plasma glucose (0.84
mmol/L, 95% CI 0.39 to 1.29) and the incidence of type 2 dia-
betes over one year (RR 0.55, 95% CI 0.44 to 0.69), and should
thus be recommended for patients with patients at high risk for
type 2 diabetes (Yamaoka 2005).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients with impaired glucose tolerance the use of acarbose
reduces the incidence of type 2 diabetes, but the effects on gly-
caemic control are limited. Acarbose has a possible effect on car-
diovascular morbidity, which has to be confirmed in other studies.
Life-style interventions remain the cornerstone of treatment for
patients at risk for type 2 diabetes. If physicians and patients feel
that an active treatment for impaired glucose tolerance is needed,
they should consider this evidence together with evidence for other
interventions, especially life-style interventions.
Implications for research
First, the disclosure of the finished - but unpublished - studies is
needed in order to confirm or refute the possible effects on cardio-
vascularmorbidity. If the evidence remains inconclusive after these
data have been incorporated in the systematic review, the results
from two ongoing long-term intervention studies on the effects of
alpha-glucosidase inhibitors for patients with IGT or IFBG may
be awaited. Otherwise, new long-term studies with a similar focus
could be initiated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
DAISI
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind
DURATION: 3 years (treatment and follow-up)
Participants COUNTRY: Netherlands
SETTING: unclear
RECRUITMENT: unclear
DIAGNOSTIC CRITERIA: 2-hour post-load BG > 8.6 mmol/L and < 11.1 mmol/L after 2 OGTTs
(WHO 1985)
NUMBER: AGI: included 61, completed 27, ITT 60, PP 32; CONTROL included 60, completed 33,
ITT 58, PP 39
SEX: ’sex ratio nearly 1:1’
AGE (YEARS (MEDIAN)): AGI 61; CONTROL 56
BMI (KG/M2 (MEAN)): ND
GLYCATED HAEMOGLOBIN: ND
Interventions Dietary advice: unclear
AGI: acarbose, week 1 50 mg OD; week 2 50 mg BID; week 3 - endpoint 30 mg TID
CONTROL: placebo, dosing schedule not described
Outcomes 1. Mortality: unclear
2. Complications related to hyperglycaemia: incidence of type 2 diabetes and ’conversion to’ normal
glucose tolerance
3. Quality of Life: unclear
4. Glycaemic control: fasting venous glucose
5. Lipids: Total- & HDL-cholesterol, triglycerides
6. Insulin levels: B-cell function and insulin sensitivity
7. Weight: unclear
8. Blood pressure: unclear
9. Adverse effects: unclear
10. Costs: unclear
Notes Sponsor: Bayer, manufacturer of acarbose
Author contacted: yes, we received the statistical report, but we were not allowed to use these data before
the manuscript of the original study was accepted for publication.
Study retrieved: databases of ongoing studies, handsearching
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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EDIT
Methods DESIGN: parallel study, 2x2 factorial design, patients randomised for both acarbose andmetformin versus
placebo
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind
DURATION: 6 years (treatment and follow-up)
Participants COUNTRY: United Kingdom
SETTING: unclear
RECRUITMENT: unclear, ’self-referred’
DIAGNOSTIC CRITERIA: Patients ’at risk’ for developing diabetes, Fasting BG 5.5-7.7 mmol/L
NUMBER: recruited 671, randomised 631
SEX: 51% Female, 49% Male
AGE (YEARS (MEAN (SD)): randomised patients 52,1 (10,0)
BMI (KG/M2 (MEAN (SD))): randomised patients 28,6 (4,5)
GLYCATED HAEMOGLOBIN (% (MEAN (SD))): all randomised patients 5.9 (0.5)
Interventions Dietary advice: unclear
2X2 Factorial design, four possible treatments:
AGI: acarbose 50 mg TID + placebo TID
CONTROL1: placebo TID + placebo TID
CONTROL2: metformin 500 mg TID + placebo TID
CONTROL3: metformin 500 mg TID + acarbose 50 mg TID
Outcomes 1. Mortality: unclear
2. Complications related to hyperglycemia: progression to type 2 diabetes
3. Quality of Life: yes
4. Glycaemic control: fasting BG
5. Lipids: ’lipid profiles’
6. Insulin levels: beta-cell function and insulin sensitivity
7. Weight: body weight
8. Blood pressure: unclear
9. Adverese effects: unclear
10. Costs: unclear
Notes Because we planned to investigate AGI monotherapy, we will not consider the outcomes for the combi-
nation group (acarbose + metformin)
Sponsor: funded by an educational grant from Bayer and Merck-Lipha
Author contacted: study currently submitted for publication, themanuscript will be made accessible when
the galley proof is available.
Study retrieved: databases of ongoing studies, handsearching, experts
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Fang 2004
Methods DESIGN: parallel
RANDOMISATION PROCEDURE: adequate
BLINDING: no mention of blinding or use of placebo
DURATION: 5 years (treatment and follow-up)
Participants COUNTRY: China
SETTING: unclear
RECRUITMENT: selected volunteers, details missing
DIAGNOSTIC CRITERIA: IGT according to WHO 1985
NUMBER: 549 volunteers screened; 178 cases of IGT included: AGI 50, CONTROL1 40, CONTROL2
48, CONTROL3 40; analysed AGI 45, CONTROL1 35, CONTROL2 44, CONTROL3 36
SEX (F/M): AGI 22/28, CONTROL1 18/22, CONTROL2 22/26, CONTROL3 22/18
AGE (YEARS (MEAN (SD)): analysed patients: AGI 50 (7), CONTROL1 47 (14), CONTROL2 50
(7), CONTROL3 49 (6)
BMI (KG/M2 (MEAN (SD))): analysed patients: AGI 24.9 (2.1), CONTROL1 24.8 (2.5), CONTROL2
25.2 (2.8), CONTROL3 25.3 (1.9)
GLYCATED HAEMOGLOBIN: ND
Interventions Dietary advice: unclear
AGI: acarbose 25-50 mg TID
CONTROL1: no treatment (common diabetes prevention education)
CONTROL2: flumamine (= metformin) 125-250 mg TID
CONTROL3: Diet and exercise: Education and dietary advice and exercise based on personal situation
Outcomes 1. Mortality: ND
2. Complications related to hyperglycaemia: incidence of type 2 diabetes
3. Quality of Life: ND
4. Glycaemic control: fasting and 2-hours post-prandial blood glucose
5. Lipids: total cholesterol & triglycerides
6. Insulin levels: ND
7. Weight: BMI
8. Blood pressure: systolic & diastolic blood pressure
9. Adverse effects: ND
10. Costs: ND
Notes Sponsor: unclear
Author contacted: yes, no reply
Study retrieved: EMBASE
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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STOP-NIDDM
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: adequate
BLINDING: double-blind
DURATION: mean 3.3 years (SD 1.5) treatment period, followed by a three months wash out period
Participants COUNTRIES: Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, Spain
SETTING: Outpatients
RECRUITMENT: through screening of high-risk populations, and in particular from first degree relatives
of patients with type 2 diabetes
DIAGNOSTIC CRITERIA: IGT (WHO 1999): 2 hour BG >=7.8 and < 11.1 mmol/L and fasting BG
>=5.6 and <7.8 mmol/L
NUMBER: randomised 1429, analysed 1368 (AGI 682, CONTROL 686); medication discontinuation,
AGI 230/682, CONTROL 130/686
SEX (F/M): analysed group AGI 353/329, CONTROL 342/344
AGE (YEARS (MEAN (SD)): analysed patients: AGI 54.3 (7.9), CONTROL 54.6 (7.9)
BMI (KG/M2 (MEAN (SD))): analysed patients: AGI 31.0 (4.3), CONTROL 30.9 (4.2)
GLYCATED HAEMOGLOBIN (% (MEAN (SD))): analysed patients: AGI 5.24 (0.74), CONTROL
5.24 (0.78)
Interventions Dietary advice: all patients were instructed to go on a weight-reduction or weight-maintenance diet and
were encouraged to exercise regularly; these instructions were reinforced at each visit
AGI: acabose, started with 50 mg (once daily) and uptitrated to 100 mg TID or maximum tolerated dose.
Mean daily dose 194 mg (SD 87)
CONTROL: placebo, dosage adjusted similar to acarbose, ’mean daily dose’ was 238 mg (SD missing)
Outcomes 1. Mortality: yes
2. Complications related to hyperglycaemia: incidence of diabetes & cardiovascular events
3. Quality of Life: ND
4. Glycaemic control: glycated haemoglobin, fasting & post-load blood glucose
5. Lipids: Total-, HDL & LDL-cholesterol, triglycerides
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight, BMI
8. Blood pressure: Diastolic & Systolic blood pressure, occurrence of hypertension
9. Adverse effects: yes
10. Costs: ND
Notes Sponsor: Bayer, manufacturer of acarbose
Author contacted: additional data sent by author
Study retrieved: PUBMED, CENTRAL, EMBASE, WOS, Handsearch, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Wang 2000
Methods DESIGN: parallel
RANDOMISATION PROCEDURE: unclear
BLINDING: not blinded
DURATION: 1 year (treatment and follow-up)
Participants COUNTRY: China
SETTING: unclear
RECRUITMENT: unclear
DIAGNOSTIC CRITERIA: IGT according to WHO 1985
NUMBER: randomised AGI 31, CONTROL 30; analysed AGI 30, CONTROL 30
SEX (F/M): AGI 15/16, CONTROL 14/16
AGE (YEARS (MEAN (SD)): AGI 64.0 (8.7), CONTROL 63.0 (7.0)
BMI (KG/M2 (MEAN (SD))): AGI 22.7 (3.4), CONTROL 21.0 (3.0)
GLYCATED HEMOGLOBIN: ND
Interventions Dietary advice: 5 hours training about diet in treatment and prevention of type 2 diabetes
AGI: acarbose 50 mg TID
CONTROL: no treatment
Outcomes 1. Mortality: ND
2. Complications related to hyperglycemia: incidence of type 2 diabetes
3. Quality of Life: ND
4. Glycaemic control: ND
5. Lipids: ND
6. Insulin levels: ND
7. Weight: ND
8. Blood pressure: ND
9. Adverese effects: yes
10. Costs: ND
Notes Sponsor: unclear
Author contacted: yes, no reply
Study retrieved: CENTRAL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
BG = Blood Glucose; BID = Bis In Die (twice daily); BMI = Body Mass Index; IGT = Impaired Glucose Tolerance; ITT = Intention
To Treat Population; ND = No Data; OD = once daily; OGTT = Oral Glucose Tolerance Test; PP = Per Protocol Population; TID
= Ter In Die (three times a day)
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
EDIP All enrolled subjects have type 2 diabetes (as defined by a 2-hours post load plasma glucose >= 11.1 mmol/L)
Mangiagli 2004 Study was not randomised
Yang 2001 No mention of randomisation in the translated manuscript. Attempts to contact the authors failed (e-mails were
rejected)
Characteristics of ongoing studies [ordered by study ID]
ABC-Study
Trial name or title Alpha-Glucosidase-Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT (ABC
Study)
Methods
Participants Patients with IGT and old myocardial infarction.
Interventions acarbose versus standard diet and exercise treatment
Outcomes Primary outcomes: 1 cardiovascular mortality; 2 hospitalisation due to cardiovascular events; Secondary
outcomes: 1 all cause mortality; 2 hospitalisation due to coronary artery disease; 3 progression of IGT to
diabetes; 4 development or deterioration of either hypertension or hyperlipidaemia; 5 deterioration of renal
function; 6 hospitalisation due to cerebrovascular disease; 7 hospitalisation due to heart failure
Starting date April 2005; last follow-up April 2009
Contact information Masafumi Kitakaze MD, PhD
Tel: 81-6-6833-5012 ext.: 2225 kitakaze@zf6.so-net.ne.jp
Notes
Tamita 2006
Trial name or title Acarbose and Secondary Prevention After Coronary Stenting
Methods
Participants patients with abnormal glucose tolerance and coronary artery disease
Interventions acarbose versus standard lifestyle modification
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Tamita 2006 (Continued)
Outcomes Primary outcome: cardiovascular event free survival time. Secondary outcomes: 1 conversion of abnormal
glucose tolerance to type 2 diabetes; 2 all cause of death; 3 occurrence of every cardiovascular event; 4
occurrence of in-stent restenosis; 5 regression of intimal plus medial complex of the carotid artery; 6 change in
fasting, 2-hour blood glucose and insulin level; 7 change in homeostasis model assessment of insulin resistance;
8 change in HbA1c; 9 change in lipid profile
Starting date May 2005; last follow-up April 2013
Contact information Koichi Tamita ,MD
Tel: +81-78-304-4321 k-tamita@kcgh.gr.jp
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Acarbose versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of type 2 diabetes
mellitus
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
2 Occurrence of death (total) 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
3 Occurrence of cardiovascular
death
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
4 Occurrence of cardiovascular
disease (any)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
5 Occurrence of myocardial
infarctions
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
6 Occurrence of angina pectoris 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
7 Occurrence of revascularisation
procedures
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
8 Occurrence of congestive heart
failure
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
9 Occurrence of cerebrovascular
events
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
10 Occurrence of peripheral
vascular events
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
11 Change in glycated
haemoglobin (%)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
11.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
12 Change in fasting blood glucose
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
12.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
13 Change in post-load blood
glucose (mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
13.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
14 Change in total cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
14.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
15 Change in HDL-cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
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15.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
16 Change in LDL-cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
16.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
17 Change in triglycerides
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
17.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
18 Change in fasting insulin levels
(pmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
18.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
19 Change in post-load insulin
levels (pmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
19.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
20 Change in body weight (Kg) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
20.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
21 Change in body mass index
(Kg/m2)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
21.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
22 Change in diastolic blood
pressure (mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
22.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
23 Change in systolic blood
pressure (mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
23.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
24 Occurrence of side effects
(total)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
24.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
25 Occurrence of gastro-intestinal
side-effects
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
25.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
Comparison 2. Acarbose versus metformin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of type 2 diabetes
mellitus
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
2 Change in fasting blood glucose
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in post-load blood
glucose (mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
4 Change in total cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
5 Change in triglycerides (mmol/l) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
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5.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
6 Change in body mass index
(Kg/m2)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
7 Change in diastolic blood
pressure (mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
8 Change in systolic blood pressure
(mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 3. Acarbose versus diet and exercise
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of type 2 diabetes
mellitus
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
2 Change in fasting blood glucose
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in post-load blood
glucose (mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
4 Change in total cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
5 Change in triglycerides (mmol/l) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
6 Change in body mass index
(Kg/m2)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
7 Change in diastolic blood
pressure (mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
8 Change in systolic blood pressure
(mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
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Comparison 4. Acarbose versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of type 2 diabetes
mellitus
2 140 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.08, 0.59]
1.1 Acarbose 100 mg TID 2 140 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.08, 0.59]
2 Change in fasting blood glucose
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in post-load blood
glucose (mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
4 Change in total cholesterol
(mmol/l)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
5 Change in triglycerides (mmol/l) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
6 Change in body mass index
(Kg/m2)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
7 Change in diastolic blood
pressure (mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
8 Change in systolic blood pressure
(mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 Acarbose 100 mg TID 1 Mean Difference (IV, Random, 95% CI) Not estimable
9 Occurrence of side effects (total) 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
10 Occurrence of gastro-intestinal
side-effects
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Acarbose 100 mg TID 1 Odds Ratio (M-H, Random, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Acarbose versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 1 Incidence of type 2 diabetes mellitus
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 221/682 285/686 0.67 [ 0.54, 0.84 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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Analysis 1.2. Comparison 1 Acarbose versus placebo, Outcome 2 Occurrence of death (total).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 2 Occurrence of death (total)
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 6/714 3/715 2.01 [ 0.50, 8.07 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.3. Comparison 1 Acarbose versus placebo, Outcome 3 Occurrence of cardiovascular death.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 3 Occurrence of cardiovascular death
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 3/714 2/715 1.50 [ 0.25, 9.03 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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Analysis 1.4. Comparison 1 Acarbose versus placebo, Outcome 4 Occurrence of cardiovascular disease
(any).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 4 Occurrence of cardiovascular disease (any)
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 15/682 32/686 0.46 [ 0.25, 0.86 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.5. Comparison 1 Acarbose versus placebo, Outcome 5 Occurrence of myocardial infarctions.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 5 Occurrence of myocardial infarctions
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 1/682 12/686 0.08 [ 0.01, 0.64 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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Analysis 1.6. Comparison 1 Acarbose versus placebo, Outcome 6 Occurrence of angina pectoris.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 6 Occurrence of angina pectoris
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 5/682 12/686 0.41 [ 0.15, 1.18 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.7. Comparison 1 Acarbose versus placebo, Outcome 7 Occurrence of revascularisation
procedures.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 7 Occurrence of revascularisation procedures
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 11/682 20/686 0.55 [ 0.26, 1.15 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
32Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Acarbose versus placebo, Outcome 8 Occurrence of congestive heart failure.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 8 Occurrence of congestive heart failure
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 0/682 2/686 0.20 [ 0.01, 4.19 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.9. Comparison 1 Acarbose versus placebo, Outcome 9 Occurrence of cerebrovascular events.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 9 Occurrence of cerebrovascular events
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 2/682 4/686 0.50 [ 0.09, 2.75 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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Analysis 1.10. Comparison 1 Acarbose versus placebo, Outcome 10 Occurrence of peripheral vascular
events.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 10 Occurrence of peripheral vascular events
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 1/682 1/686 1.01 [ 0.06, 16.11 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.11. Comparison 1 Acarbose versus placebo, Outcome 11 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 11 Change in glycated haemoglobin (%)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 616 0.13 (0.64) 622 0.19 (0.73) -0.06 [ -0.14, 0.02 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 1.12. Comparison 1 Acarbose versus placebo, Outcome 12 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 12 Change in fasting blood glucose (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 676 0.05 (1.14) 683 0.12 (1.16) -0.07 [ -0.19, 0.05 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
Analysis 1.13. Comparison 1 Acarbose versus placebo, Outcome 13 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 13 Change in post-load blood glucose (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 656 -0.21 (3.12) 668 0.4 (3.28) -0.61 [ -0.95, -0.27 ]
-10 -5 0 5 10
Favours acarbose Favours placebo
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Analysis 1.14. Comparison 1 Acarbose versus placebo, Outcome 14 Change in total cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 14 Change in total cholesterol (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 621 -0.13 (1) 632 -0.14 (0.96) 0.01 [ -0.10, 0.12 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
Analysis 1.15. Comparison 1 Acarbose versus placebo, Outcome 15 Change in HDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 15 Change in HDL-cholesterol (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 618 0.09 (0.34) 632 0.07 (0.26) 0.02 [ -0.01, 0.05 ]
-1 -0.5 0 0.5 1
Favours acarbose Favours placebo
36Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.16. Comparison 1 Acarbose versus placebo, Outcome 16 Change in LDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 16 Change in LDL-cholesterol (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 587 -0.16 (0.87) 602 -0.13 (1.02) -0.03 [ -0.14, 0.08 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
Analysis 1.17. Comparison 1 Acarbose versus placebo, Outcome 17 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 17 Change in triglycerides (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 622 -0.18 (1.1) 633 -0.11 (0.94) -0.07 [ -0.18, 0.04 ]
-1 -0.5 0 0.5 1
Favours acarbose Favours placebo
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Analysis 1.18. Comparison 1 Acarbose versus placebo, Outcome 18 Change in fasting insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 18 Change in fasting insulin levels (pmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 629 -2.91 (58.05) 643 0.65 (103.38) -3.56 [ -12.75, 5.63 ]
-100 -50 0 50 100
Favours acarbose Favours placebo
Analysis 1.19. Comparison 1 Acarbose versus placebo, Outcome 19 Change in post-load insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 19 Change in post-load insulin levels (pmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 620 -52.13 (391.43) 634 -64.53 (403.93) 12.40 [ -31.62, 56.42 ]
-1000 -500 0 500 1000
Favours acarbose Favours placebo
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Analysis 1.20. Comparison 1 Acarbose versus placebo, Outcome 20 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 20 Change in body weight (Kg)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 677 -0.64 (6.7) 682 0.54 (5.22) -1.18 [ -1.82, -0.54 ]
-10 -5 0 5 10
Favours acarbose Favours placebo
Analysis 1.21. Comparison 1 Acarbose versus placebo, Outcome 21 Change in body mass index (Kg/m2).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 21 Change in body mass index (Kg/m2)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 677 -0.34 (1.98) 681 -0.03 (1.94) -0.31 [ -0.52, -0.10 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 1.22. Comparison 1 Acarbose versus placebo, Outcome 22 Change in diastolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 22 Change in diastolic blood pressure (mmHg)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 677 -1.31 (9.18) 682 -0.99 (9.22) -0.32 [ -1.30, 0.66 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
Analysis 1.23. Comparison 1 Acarbose versus placebo, Outcome 23 Change in systolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 23 Change in systolic blood pressure (mmHg)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
STOP-NIDDM 677 0.03 (15.09) 682 0.44 (15.6) -0.41 [ -2.04, 1.22 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 1.24. Comparison 1 Acarbose versus placebo, Outcome 24 Occurrence of side effects (total).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 24 Occurrence of side effects (total)
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 698/714 675/715 2.59 [ 1.43, 4.66 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 1.25. Comparison 1 Acarbose versus placebo, Outcome 25 Occurrence of gastro-intestinal side-
effects.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 1 Acarbose versus placebo
Outcome: 25 Occurrence of gastro-intestinal side-effects
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
STOP-NIDDM 597/714 426/715 3.46 [ 2.70, 4.44 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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Analysis 2.1. Comparison 2 Acarbose versus metformin, Outcome 1 Incidence of type 2 diabetes mellitus.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 1 Incidence of type 2 diabetes mellitus
Study or subgroup Acarbose Metformin Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
Fang 2004 6/45 9/44 0.60 [ 0.19, 1.85 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours metformin
Analysis 2.2. Comparison 2 Acarbose versus metformin, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 2 Change in fasting blood glucose (mmol/l)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.75 (1.7) 44 -0.36 (1.9) -0.39 [ -1.14, 0.36 ]
-4 -2 0 2 4
Favours acarbose Favours metformin
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Analysis 2.3. Comparison 2 Acarbose versus metformin, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 3 Change in post-load blood glucose (mmol/l)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -1.38 (2) 44 0.02 (2.1) -1.40 [ -2.25, -0.55 ]
-10 -5 0 5 10
Favours acarbose Favours metformin
Analysis 2.4. Comparison 2 Acarbose versus metformin, Outcome 4 Change in total cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 4 Change in total cholesterol (mmol/l)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (1.9) 44 -1.6 (1.5) 0.90 [ 0.19, 1.61 ]
-4 -2 0 2 4
Favours acarbose Favours metformin
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Analysis 2.5. Comparison 2 Acarbose versus metformin, Outcome 5 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 5 Change in triglycerides (mmol/l)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.3 (1.5) 44 -1 (2.1) 0.70 [ -0.06, 1.46 ]
-1 -0.5 0 0.5 1
Favours acarbose Favours metformin
Analysis 2.6. Comparison 2 Acarbose versus metformin, Outcome 6 Change in body mass index (Kg/m2).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 6 Change in body mass index (Kg/m2)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (2.25) 44 -0.3 (3.01) -0.40 [ -1.51, 0.71 ]
-4 -2 0 2 4
Favours acarbose Favours metformin
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Analysis 2.7. Comparison 2 Acarbose versus metformin, Outcome 7 Change in diastolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 7 Change in diastolic blood pressure (mmHg)
Study or subgroup Acarbose Metformin
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 1 (7.67) 44 -5 (7.67) 6.00 [ 2.81, 9.19 ]
-4 -2 0 2 4
Favours acarbose Favours metformin
Analysis 2.8. Comparison 2 Acarbose versus metformin, Outcome 8 Change in systolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 2 Acarbose versus metformin
Outcome: 8 Change in systolic blood pressure (mmHg)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -6 (14.81) 44 -7 (14.81) 1.00 [ -5.15, 7.15 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 3.1. Comparison 3 Acarbose versus diet and exercise, Outcome 1 Incidence of type 2 diabetes
mellitus.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 1 Incidence of type 2 diabetes mellitus
Study or subgroup Acarbose Diet % exercise Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
Fang 2004 6/45 12/36 0.31 [ 0.10, 0.93 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours diet % exer
Analysis 3.2. Comparison 3 Acarbose versus diet and exercise, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 2 Change in fasting blood glucose (mmol/l)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.75 (1.7) 36 0.62 (2.2) -1.37 [ -2.24, -0.50 ]
-4 -2 0 2 4
Favours acarbose Favours diet % exer
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Analysis 3.3. Comparison 3 Acarbose versus diet and exercise, Outcome 3 Change in post-load blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 3 Change in post-load blood glucose (mmol/l)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -1.38 (2) 36 1.41 (2.5) -2.79 [ -3.79, -1.79 ]
-10 -5 0 5 10
Favours acarbose Favours diet % exer
Analysis 3.4. Comparison 3 Acarbose versus diet and exercise, Outcome 4 Change in total cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 4 Change in total cholesterol (mmol/l)
Study or subgroup Acarbose Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (1.9) 36 -0.2 (1.9) -0.50 [ -1.33, 0.33 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 3.5. Comparison 3 Acarbose versus diet and exercise, Outcome 5 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 5 Change in triglycerides (mmol/l)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.3 (1.5) 36 -0.2 (1.5) -0.10 [ -0.76, 0.56 ]
-1 -0.5 0 0.5 1
Favours acarbose Favours diet % exer
Analysis 3.6. Comparison 3 Acarbose versus diet and exercise, Outcome 6 Change in body mass index
(Kg/m2).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 6 Change in body mass index (Kg/m2)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (2.25) 36 -0.5 (2.03) -0.20 [ -1.13, 0.73 ]
-4 -2 0 2 4
Favours acarbose Favours diet % exer
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Analysis 3.7. Comparison 3 Acarbose versus diet and exercise, Outcome 7 Change in diastolic blood
pressure (mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 7 Change in diastolic blood pressure (mmHg)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 1 (7.67) 36 -2 (6.57) 3.00 [ -0.10, 6.10 ]
-4 -2 0 2 4
Favours acarbose Favours diet % exer
Analysis 3.8. Comparison 3 Acarbose versus diet and exercise, Outcome 8 Change in systolic blood
pressure (mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 3 Acarbose versus diet and exercise
Outcome: 8 Change in systolic blood pressure (mmHg)
Study or subgroup Acarbose Diet % exercise
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -6 (14.81) 36 0 (13.72) -6.00 [ -12.23, 0.23 ]
-4 -2 0 2 4
Favours acarbose Favours diet % exer
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Analysis 4.1. Comparison 4 Acarbose versus no treatment, Outcome 1 Incidence of type 2 diabetes mellitus.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 1 Incidence of type 2 diabetes mellitus
Study or subgroup Acarbose No treatment Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
Fang 2004 6/45 15/35 82.0 % 0.21 [ 0.07, 0.61 ]
Wang 2000 1/30 3/30 18.0 % 0.31 [ 0.03, 3.17 ]
Total (95% CI) 75 65 100.0 % 0.22 [ 0.08, 0.59 ]
Total events: 7 (Acarbose), 18 (No treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours no treatment
Analysis 4.2. Comparison 4 Acarbose versus no treatment, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 2 Change in fasting blood glucose (mmol/l)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.75 (1.7) 35 0.64 (2.1) -1.39 [ -2.24, -0.54 ]
-4 -2 0 2 4
Favours acarbose Favours no treatment
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Analysis 4.3. Comparison 4 Acarbose versus no treatment, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 3 Change in post-load blood glucose (mmol/l)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -1.38 (2) 35 3.15 (2.4) -4.53 [ -5.52, -3.54 ]
-10 -5 0 5 10
Favours acarbose Favours no treatment
Analysis 4.4. Comparison 4 Acarbose versus no treatment, Outcome 4 Change in total cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 4 Change in total cholesterol (mmol/l)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (1.9) 35 0.3 (1.8) -1.00 [ -1.81, -0.19 ]
-4 -2 0 2 4
Favours acarbose Favours no treatment
51Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 Acarbose versus no treatment, Outcome 5 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 5 Change in triglycerides (mmol/l)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.3 (1.5) 35 0 (2.1) -0.30 [ -1.12, 0.52 ]
-1 -0.5 0 0.5 1
Favours acarbose Favours no treatment
Analysis 4.6. Comparison 4 Acarbose versus no treatment, Outcome 6 Change in body mass index (Kg/m2).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 6 Change in body mass index (Kg/m2)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -0.7 (2.25) 35 0.4 (2.69) -1.10 [ -2.21, 0.01 ]
-4 -2 0 2 4
Favours acarbose Favours no treatment
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Analysis 4.7. Comparison 4 Acarbose versus no treatment, Outcome 7 Change in diastolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 7 Change in diastolic blood pressure (mmHg)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 1 (7.67) 35 -2 (6.57) 3.00 [ -0.12, 6.12 ]
-4 -2 0 2 4
Favours acarbose Favours no treatment
Analysis 4.8. Comparison 4 Acarbose versus no treatment, Outcome 8 Change in systolic blood pressure
(mmHg).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 8 Change in systolic blood pressure (mmHg)
Study or subgroup Acarbose No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Fang 2004 45 -6 (14.81) 35 0 (13.72) -6.00 [ -12.28, 0.28 ]
-4 -2 0 2 4
Favours acarbose Favours no treatment
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Analysis 4.9. Comparison 4 Acarbose versus no treatment, Outcome 9 Occurrence of side effects (total).
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 9 Occurrence of side effects (total)
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
Wang 2000 2/30 0/30 5.35 [ 0.25, 116.31 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
Analysis 4.10. Comparison 4 Acarbose versus no treatment, Outcome 10 Occurrence of gastro-intestinal
side-effects.
Review: Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose
Comparison: 4 Acarbose versus no treatment
Outcome: 10 Occurrence of gastro-intestinal side-effects
Study or subgroup Acarbose Placebo Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acarbose 100 mg TID
Wang 2000 2/30 0/30 5.35 [ 0.25, 116.31 ]
0.1 0.2 0.5 1 2 5 10
Favours acarbose Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias
Study Randomi-
sation
Allocation
Conceal.
Treatment
Blinding
ITT anal-
ysis
Quantity
drop-out
Selective
drop-out
Blind out-
come-
assess
Analyses
Blinding
Overall
Quality
A = Ad-
equate; B
= Not ade-
quate / un-
clear
A = Ad-
equate; B
= Not ade-
quate / un-
clear
A = ade-
quate, B =
men-
tioning of
blind-
ing but ex-
actmethod
unclear, C
= non-
blinded,
inad-
equate or
unknown
A = ade-
quate, B =
ITT inad-
equate, C
= Unclear
or no re-
ported
data on
drop-out /
loss-to-
follow-up
A<15%,B
>= 15% or
unknown
A = dif-
ference in
drop-
out rate in
main
groups
< 10%, B
>= 10% or
unknown
A = ade-
quate, B =
men-
tioning of
blind-
ing but ex-
actmethod
unclear, C
= non-
blinded,
inad-
equate or
unknown
A = ade-
quate, B =
men-
tioning of
blind-
ing but ex-
actmethod
unclear, C
= non-
blinded,
inad-
equate or
unknown
A = all
quality cri-
teria met;
B = one or
more qual-
ity criteria
only par-
tially met;
C = one or
more qual-
ity criteria
not met
DAISI B B B C B A B B C
EDIT B B B C B B B B C
Fang 2004 A B C B A A B B C
STOP-
NIDDM
A A A B A A A B A
Wang
2000
B B C B A A B B C
A P P E N D I C E S
Appendix 1. Search strategy
Electronic searches
Unless otherwise stated, search terms are free text terms; MesH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the asterisk (*) stands for any character(s); tw = text word; pt = publication type; sh = MeSH; adj = adjacent.
#1 Alpha-glucosidase inhibitors (Van de Laar 2005)
“Acarbose”[MeSH] OR acarbos* [tw] OR bayg5421 OR bay 5421 [tw] OR glucobay [tw] OR precos* [tw] OR prandas* [tw] OR
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(Continued)
akarbos* [tw] OR miglitol [tw] OR glyset [tw] OR diastabol [tw] OR baym1099 [tw] OR bay 1099 [tw] OR voglibos* [tw] OR
(basen NOT basen [au]) OR emiglitat* [tw] OR alpha-glucosidase inhibitor [tw] OR glucosidase inhibitor [tw] OR alpha-glucosidase
inhibitors [tw] OR glucosidase inhibitors [tw]
#2 Controlled trials (Robinson 2002)
(Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation
[mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (clinical trial
[tw]) OR ((singl*[tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (latin square [tw])
OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation
studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv*
[tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh])
#3 Impaired Glucose Tolerance or Impaired Fasting Blood Glucose
“Glucose Intolerance”[MeSH]OR“DiabetesMellitus, Type II/prevention and control”[MeSH]OR“Glucose Tolerance Test”[MeSH]
OR“InsulinResistance/drug effects”[MeSH]OR“Metabolic SyndromeX”[MeSH]OR“impaired fasting glucose” [tw]OR “impaired
fasting blood glucose” [tw] OR “impaired fasting bloodglucose” [tw] OR “impaired fasting glycaemia” [tw] OR “impaired fasting
glycemia” [tw] OR impaired glucose toleran* [tw] OR impaired glucose stat* [tw] OR impaired glucose-respons* [tw] OR impaired
glucose control* [tw] OR IGT [tw] OR glucose intoleran* [tw] OR impaired glucose regul* [tw] OR impaired glucose metab* [tw]
OR impaired glucose homeost* [tw] OR reduced glucose metabolism* [tw] OR reduced glucose toleran* [tw] OR glucose intolerant*
[tw] OR glucose tolerance test* [tw]OR prediabet* [tw] ORpraediabet* [tw] OR “pre diabetes” [tw] OR “prae diabetes” [tw] OR “pre
diabetic” [tw] OR “prae diabetic” [tw] OR “pre diabetics” [tw] OR “prae diabetics” [tw] OR metabolic syndr* [tw] OR “syndrome
X” [tw] OR borderline diabet* [tw] OR mild diabet* [tw] OR insulin resistan* [tw] OR impaired insulin secret* [tw] OR reduced
insulin secret* [tw]
Whole search: #1 AND #2 AND #3
These searches can be cut and pasted into PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi)
Appendix 2. Outcomes: Acarbose (ACA) versus placebo (PLA)
Outcome STOP-NIDDM
(ACA)
STOP-NIDDM
(PLA)
DAISI (ACA) DAISI (PLA) EDIT (ACA) EDIT (PLA)
Mortality (n/N) Total death: 6/
714; cardiovas-
cular death: 3/
714
Total death: 3/
715; cardiovas-
cular death: 2/
715
No Data No Data No Data No Data
Incidence of
Type 2 Diabetes
Mellitus (n/N)
221/682 285/686 No Data No Data In those with IGT
at baseline, RR was
reduced with acar-
bose (RR = 0.
66, P=0.046) (at 6
years)
No Data
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(Continued)
Incidence of car-
diovascular mor-
bidity (n/N)
All cardiovascu-
lar event:
15/682, myocar-
dial infarction 1/
682, angina 5/
682, revas-
cularization pro-
cedure
11/682, cardio-
vascular death 1/
682, congestive
heart failure 0/
682, cerebrovas-
cular event or
stroke 2/682, pe-
ripheral vascular
disease 1/682
All cardiovascu-
lar event: 32/
686, myocardial
infarction
12/686, angina
12/686, revascu-
larization proce-
dure
20/686, cardio-
vascular death 2/
686, congestive
heart failure 2/
686, cerebrovas-
cular event or
stroke 4/686, pe-
ripheral vascular
disease 1/686
No Data No Data No Data No Data
Glycated haemo-
globin (%)
Baseline (n=641)
5.24 (±0.74)
, Endpoint (n=
657) 5.38 (± 0.
78), Change (n=
616) 0.13 (± 0.
64)
Baseline (n=640)
5.24 (± 0.78)
, Endpoint (n=
667) 5.43 (± 0.
84), Change (n=
622) 0.19 (± 0.
73)
No Data No Data No Data No Data
Fasting blood
glucose (mmol/
L)
Baseline (n=682)
6.23 (± 0.50)
, Endpoint (n=
676) 6.27 (± 1.
17), Change (n=
676) 0.05 (± 1.
14)
Baseline (n=686)
6.24 (± 0.53)
, Endpoint (n=
683) 6.36 (± 1.
24), Change (n=
683) 0.12 (± 1.
16)
No Data No Data No Data No Data
Post-load blood
glucose (mmol/
L)
Baseline (n=682)
9.26 (± 1.06)
, Endpoint (n=
656) 9.05 (± 3.
20), Change (n=
656) -0.21 (± 3.
12)
Baseline (n=686)
9.25 (± 1.01)
, Endpoint (n=
668) 9.64 (± 3.
40), Change (n=
668) 0.40 (± 3.
28)
No Data No Data At 3 years, com-
pared to placebo: -
0.4 mmol/L (P=0.
0075) [note: half
of these pa-
tients also use met-
formin, due to the
2x2 factorial de-
sign]
No Data
Plasma Lipids
(mmol/L)
Total choles-
terol: Baseline
(n=648) 5.76 (±
1.04), Endpoint
(n=655) 5.64 (±
Total choles-
terol: Baseline
(n=647) 5.61 (±
0.99), Endpoint
(n=669) 5.49 (±
No Data No Data At
3 years, compared
to placebo: triglyc-
erides -0,14mmol/
L (P=0.036) [note:
No Data
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1.05),
Change (n=621)
-0.13 (± 1.00)
; HDL choles-
terol: Baseline
(n=645) 1.19 (±
0.32), Endpoint
(n=655) 1.29 (±
0.43),
Change (n=618)
0.09 (± 0.34);
LDL cholesterol:
Baseline (n=614)
3.66 (± 0.91)
, Endpoint (n=
652) 3.49 (± 0.
93), Change (n=
587) -0.16 (± 0.
87); Triglyc-
erides: Baseline
(n=649) 2.07 (±
1.10), Endpoint
(n=655) 1.90
(± 1.25), Change
(n=622) -0.18 (±
1.10)
1.01),
Change (n=632)
-0.14 (± 0.96)
; HDL choles-
terol: Baseline
(n=647) 1.17 (±
0.33), Endpoint
(n=669) 1.24 (±
0.34),
Change (n=632)
0.07 (± 0.26);
LDL cholesterol:
Baseline (n=618)
3.54 (± 0.90)
, Endpoint (n=
662) 3.38 (± 0.
98), Change (n=
602) -0.13 (± 1.
02); Triglyc-
erides: Baseline
(n=648) 2.07 (±
1.17), Endpoint
(n=669) 2.01
(± 1.36), Change
(n=633) -0.11 (±
0.94)
half of these pa-
tients also use met-
formin, due to the
2x2 factorial de-
sign] Other lipids:
No data
Blood pressure
(mmHg)
Diastolic blood
pressure:
Baseline (n=681)
82.77 (± 9.37)
, Endpoint (n=
677) 81.47 (± 8.
75), Change (n=
677) -1.31
(± 9.18); Systolic
blood pressure:
Baseline (n=681)
131.43 (± 16.33)
, Endpoint (n=
677) 131.52 (±
15.42), Change
(n=677) 0.03 (±
15.09)
Diastolic blood
pressure:
Baseline (n=686)
82.02 (± 9.29)
, Endpoint (n=
682) 81.08 (± 9.
04), Change (n=
682) -0.99
(± 9.22); Systolic
blood pressure:
Baseline (n=686)
130.85 (± 16.21)
, Endpoint (n=
682) 131.28 (±
15.86), Change
(n=682) 0.44 (±
15.60)
No Data No Data No Data No Data
Fasting and
post-load insulin
(pmol/L) and c-
peptide (nmol/
L)
Fasting insulin:
Baseline (n=664)
99.93 (± 58.51)
, Endpoint (n=
Fasting insulin:
Baseline (n=664)
97.35 (± 52.39)
, Endpoint (n=
No Data No Data No Data No Data
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646)
95.64 (± 62.35),
Change (n=629)
-2.91 (± 58.05);
Post-load
insulin: Baseline
(n=658) 606.37
(± 437.46), End-
point (n=642)
548.95 (± 451.
19), Change (n=
620) -52.13 (±
391.43)
664) 97.
23 (± 100.89),
Change (n=643)
0.65 (± 103.38);
Post-load
insulin: Baseline
(n=657) 597.99
(± 414.38), End-
point (n=661)
535.12 (± 436.
74), Change (n=
634) -64.53 (±
403.93)
Body
weight (Kg) /
BodyMass Index
(Kg/m2)
Body weight:
Baseline (n=681)
87.63 (± 15.29)
, Endpoint (n=
677)
86.95 (± 15.31),
Change (n=677)
-0.64 grams (± 6.
70); Body mass
index:
Baseline (n=682)
30.99 (± 4.30)
, Endpoint (n=
677) 30.64 (± 4.
62), Change (n=
677) -0.34 (± 1.
98)
Body weight:
Baseline (n=686)
87.01 (± 14.14)
, Endpoint (n=
682)
87.57 (± 15.23),
Change (n=682)
0.54 grams (± 5.
22); Body mass
index:
Baseline (n=685)
30.87 (± 4.17)
, Endpoint (n=
681) 30.82 (± 4.
70), Change (n=
681) -0.03 (± 1.
94)
No Data No Data No Data No Data
Adverse events
(AE) (n/N)
All AEs: 698/
714; Gastro-in-
testinal AEs:
597/714
All AEs: 675/
715; Gastro-in-
testinal AEs:
426/715
No Data No Data No Data No Data
Costs / Compli-
ance
No Data No Data No Data No Data No Data No Data
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Appendix 3. Adjustment for high discontinuation rate in acarbose arm of STOP-NIDDM study
Outcome Without correction With correction
Incidence of type 2 diabetes Effect size (OR) 0.67 (0.54 to 0.84) Effect size (OR) 0.78 (0.63 to 0.97)
Incidence of any cardiovascular disease Effect size (OR) 0.46 (0.25 to 0.86) Effect size (OR) 0.52 (0.29 to 0.95)
Incidence of myocardial infarctions Effect size (OR) 0.08 (0.01 to 0.64) Effect size (OR) 0.08 (0.01 to 0.64)
Incidence of angina pectoris Effect size (OR) 0.41 (0.15 to 1.18) Effect size (OR) 0.50 (0.19 to 1.34)
Incidence of revascularization procedures Effect size (OR) 0.55 (0.26 to 1.15) Effect size (OR) 0.60 (0.29 to 1.23)
Incidence of congestive heart failure Effect size (OR) 0.20 (0.01 to 4.19) Effect size (OR) 0.20 (0.01 to 4.19)
Incidence of cerebrovascular events Effect size (OR) 0.50 (0.09 to 2.75) Effect size (OR) 0.50 (0.09 to 2.75)
Incidence of peripheral vascular events Effect size (OR) 1.01 (0.06 to 16.11) Effect size (OR) 1.01 (0.06 to 16.11)
Appendix 4. Outcomes: Acarbose (ACA) versus metformin (MET)
Outcome EDIT (ACA) EDIT (MET) Fang 2004 (ACA) Fang 2004 (MET)
Mortality (n/N) No Data No Data No Data No Data
Incidence of Type 2 Di-
abetes Mellitus (n/N)
No Data No Data 6/45 9/44
Incidence of cardiovas-
cular morbidity (n/N)
No Data No Data No Data No Data
Glycated haemoglobin
(%)
No Data No Data No Data No Data
Fasting blood glucose
(mmol/L)
No Data No Data Baseline (n=50) 6.45 (± 1.9), End-
point (n=45) 5.7 (± 0.7), Change
(n=45) -0.75 (± 1.7)
Baseline (n=48) 6.26 (± 2.1), End-
point (n=44) 5.9 (± 0.7), Change
(n=44) -0.36 (± 1.9)
Post-load blood glucose
(mmol/L)
No Data No Data Baseline (n=50) 8.38 (± 1.9), End-
point (n=45) 7.0 (± 1.8), Change
(n=45) -1.38 (± 2.0
Baseline (n=48) 7.48 (± 1.9), End-
point (n=44) 7.5 (± 1.9), Change
(n=44) 0.02 (± 2.1)
Plasma Lipids (mmol/L) No Data No Data Total cholesterol: Baseline (n=50)
6.3 (± 1.8), Endpoint (n=45) 5.6
(± 1.7), Change (n=45) -0.7 (± 1.9)
Total cholesterol: Baseline (n=48)
6.5 (± 1.5), Endpoint (n=44) 4.9
(± 1.2), Change (n=44) -1.6 (± 1.5)
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(Continued)
; Triglycerides: Baseline (n=50) 1.9
(± 1.4), Endpoint (n=45) 1.6 (± 1.
4), Change (n=45) -0.3 (± 1.5)
; Triglycerides: Baseline (n=48) 2.5
(± 2.2), Endpoint (n=44) 1.5 (± 0.
5), Change (n=44) -1.0 (± 2.1)
Blood pressure (mmHg) No Data No Data Diastolic blood pressure: Baseline
(n=50) 82 (± 7), Endpoint (n=45)
83 (± 7), Change (n=45) 1 (± 7.67)
; Systolic blood pressure: Baseline
(n=50) 130 (± 14), Endpoint (n=
45) 124 (± 13), Change (n=45) -6
(± 14.81)
Diastolic blood pressure: Baseline
(n=48) 85 (± 7), Endpoint (n=44)
80 (±7),Change (n=44) -5 (±7.67)
; Systolic blood pressure: Baseline
(n=48) 132 (± 14), Endpoint (n=
44) 125 (± 13), Change (n=44) -7
(± 14.81)
Fasting and post-load in-
sulin (pmol/L) and c-
peptide (nmol/L)
No Data No Data No Data No Data
Body weight (Kg) / Body
Mass Index (Kg/m2)
No Data No Data Body mass index: Baseline (n=50)
24.9 (± 2.1), Endpoint (n=45) 24.
2 (± 2.0), Change (n=45) -0.7 (± 2.
25)
Body mass index: Baseline (n=48)
25.2 (± 2.8), Endpoint (n=44) 24.
9 (± 2.7), Change (n=44) -0.3 (± 3.
01)
Adverse events (AE) (n/
N)
No Data No Data No Data No Data
Costs / Compliance No Data No Data No Data No Data
Appendix 5. Outcomes: Acarbose (ACA) versus diet and exercise (DIE)
Outcome Fang 2004 (ACA) Fang 2004 (DIE)
Mortality (n/N) No Data No Data
Incidence of Type 2 Diabetes Mellitus (n/
N)
6/45 12/36
Incidence of cardiovascular morbidity (n/
N)
No Data No Data
Glycated haemoglobin (%) No Data No Data
Fasting blood glucose (mmol/L) Baseline (n=50) 6.45 (± 1.9), Endpoint (n=
45) 5.7 (± 0.7), Change (n=45) -0.75 (± 1.
7)
Baseline (n=40) 5.58 (± 2.4), Endpoint (n=
36) 6.2 (± 0.6), Change (n=36) 0.62 (± 2.
2)
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Post-load blood glucose (mmol/L) Baseline (n=50) 8.38 (± 1.9), Endpoint (n=
45) 7.0 (± 1.8), Change (n=45) -1.38 (± 2.
0
Baseline (n=40) 6.99 (± 2.1), Endpoint (n=
36) 8.4 (± 2.4), Change (n=36) 1.41 (± 2.
5)
Plasma Lipids (mmol/L) Total cholesterol: Baseline (n=50) 6.3 (± 1.
8), Endpoint (n=45) 5.6 (± 1.7), Change
(n=45) -0.7 (± 1.9); Triglycerides: Baseline
(n=50) 1.9 (± 1.4), Endpoint (n=45) 1.6 (±
1.4), Change (n=45) -0.3 (± 1.5)
Total cholesterol: Baseline (n=40) 6.0 (± 1.
6), Endpoint (n=36) 5.8 (± 1.8), Change
(n=36) -0.2 (± 1.9); Triglycerides: Baseline
(n=40) 1.9 (± 1.3), Endpoint (n=36) 1.7 (±
1.5), Change (n=36) -0.2 (± 1.5)
Blood pressure (mmHg) Diastolic blood pressure: Baseline (n=50)
82 (±7), Endpoint (n=45) 83 (±7),Change
(n=45) 1 (± 7.67); Systolic blood pressure:
Baseline (n=50) 130 (± 14), Endpoint (n=
45) 124 (± 13), Change (n=45) -6 (± 14.
81)
Diastolic blood pressure: Baseline (n=40)
86 (±6), Endpoint (n=36) 84 (±6),Change
(n=36) -2 (± 6.57); Systolic blood pressure:
Baseline (n=40) 126 (± 13), Endpoint (n=
36) 126 (± 12), Change (n=36) 0 (± 13.72)
Fasting and post-load insulin (pmol/L) and
c-peptide (nmol/L)
No Data No Data
Body weight (Kg) / Body Mass Index (Kg/
m2)
Body mass index: Baseline (n=50) 24.9
(± 2.1), Endpoint (n=45) 24.2 (± 2.0),
Change (n=45) -0.7 (± 2.25)
Body mass index: Baseline (n=40) 25.3
(± 1.9), Endpoint (n=36) 24.8 (± 1.8),
Change (n=36) -0.5 (± 2.03)
Adverse events (AE) (n/N) No Data No Data
Costs / Compliance No Data No Data
Appendix 6. Outcomes: Acarbose (ACA) versus no treatment (NO)
Outcome Fang 2004 (ACA) Fang 2004 (NO) Wang 2000 (ACA) Wang 2000 (NO)
Mortality (n/N) No Data No Data No Data No Data
Incidence of Type 2 Di-
abetes Mellitus (n/N)
6/45 15/35 Type 2 diabetes: 1/30,
persisting IGT: 20/30,
normal glucose toler-
ance: 9/30
Type 2 diabetes: 3/30,
persisting IGT: 25/30,
normal glucose toler-
ance: 2/30
Incidence of cardiovas-
cular morbidity (n/N)
No Data No Data No Data No Data
Glycated haemoglobin
(%)
No Data No Data No Data No Data
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Fasting blood glucose
(mmol/L)
Baseline (n=50) 6.45 (±
1.9), Endpoint (n=45) 5.
7 (± 0.7), Change (n=45)
-0.75 (± 1.7)
Baseline (n=40) 5.66 (±
2.3), Endpoint (n=35) 6.
3 (± 1.2), Change (n=35)
0.64 (± 2.1)
No Data No Data
Post-load blood glucose
(mmol/L)
Baseline (n=50) 8.38 (±
1.9), Endpoint (n=45) 7.
0 (± 1.8), Change (n=45)
-1.38 (± 2.0
Baseline (n=40) 6.35 (±
2.2), Endpoint 9.5 (± 2.
2), Change (n=35) 3.15
(± 2.4)
No Data No Data
Plasma Lipids (mmol/L) Total cholesterol: Base-
line (n=50) 6.3 (± 1.8),
Endpoint (n=45) 5.6 (±
1.7), Change (n=45) -0.
7 (± 1.9); Triglycerides:
Baseline (n=50) 1.9 (± 1.
4), Endpoint (n=45) 1.6
(± 1.4), Change (n=45) -
0.3 (± 1.5)
Total cholesterol: Base-
line (n=40) 5.7 (± 1.7),
Endpoint (n=35) 6.0 (±
1.6), Change (n=35) 0.
3 (± 1.8); Triglycerides:
Baseline (n=40) 1.9 (± 1.
3), Endpoint (n=35) 1.9
(± 1.3), Change (n=35)
0.0 (± 2.1)
No Data No Data
Blood pressure (mmHg) Diastolic blood pressure:
Baseline (n=50) 82 (±
7), Endpoint (n=45) 83
(± 7), Change (n=45) 1
(± 7.67); Systolic blood
pressure: Baseline (n=
50) 130 (± 14), End-
point (n=45) 124 (± 13),
Change (n=45) -6 (± 14.
81)
Diastolic blood pressure:
Baseline (n=40) 84 (±
6), Endpoint (n=35) 82
(± 6), Change (n=35) -2
(± 6.57); Systolic blood
pressure: Baseline (n=
40) 128 (± 13), End-
point (n=35) 128 (± 12),
Change (n=35) 0 (± 13.
72)
No Data No Data
Fasting and post-load in-
sulin (pmol/L) and c-
peptide (nmol/L)
No Data No Data No Data No Data
Body weight (Kg) / Body
Mass Index (Kg/m2)
Body mass index: Base-
line (n=50) 24.9 (± 2.1)
, Endpoint (n=45) 24.2
(± 2.0), Change (n=45) -
0.7 (± 2.25)
Body mass index: Base-
line (n=40) 24.8 (± 2.5),
Endpoint (n=35) 25.2 (±
2.4), Change (n=35) 0.4
(± 2.69)
No Data No Data
Adverse events (AE) (n/
N)
No Data No Data 2/30 0/30
Costs / Compliance No Data No Data No Data No Data
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